<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For The Fiscal Year Ended December 31, 1998
Commission File Number: 1-12529
NETMED, INC.
(Exact name of registrant as specified in its charter)
OHIO 31-1282391
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
6189 MEMORIAL DRIVE
DUBLIN, OHIO 43017
(Address of principal executive offices,
including zip code)
(614) 793-9356
(Registrant's telephone number,
including area code)
Securities registered pursuant to Section 12(b) of the Act:
COMMON SHARES, NO PAR VALUE
(Title of Class)
Securities registered pursuant to Section 12(g) of the Act: None
The registrant has filed all reports required to be filed by Section 13
or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such
reports), and has been subject to the filing requirements for at least the past
90 days.
Indicate by check mark if disclosure of delinquent filers pursuant to
Item 405 of Regulation S-B is not contained herein, and will not be contained,
to the best of registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. [ ]
The aggregate market value of the registrant's common equity held by
non-affiliates of the registrant was approximately $1,319,964 on March 18, 1999.
There were 12,363,840 shares of the Registrant's Common Shares
outstanding on March 25, 1999.
DOCUMENTS INCORPORATED BY REFERENCE
None.
<PAGE> 2
PART I
ITEM 1. DESCRIPTION OF BUSINESS.
GENERAL
NetMed, Inc. ("NetMed" or the "Company") is an Ohio corporation engaged
in the business of acquiring, developing and marketing medical and
health-related technologies. The principal business activity of the Company is
the marketing of the PAPNET(R) Testing System, a proprietary product of
Neuromedical Systems, Inc. ("NSI"), pursuant to a license agreement with NSI.
The PAPNET Testing System is a semi-automated cancer detection system for the
review of cell, tissue or body fluid specimens, including cervical cytology
specimens. Slides containing cytology specimens are processed using the PAPNET
Testing System (either by the laboratory at its own facilities or at one of
NSI's central facilities) which produces processed images for evaluation by the
laboratory's NSI-trained cytotechnologists. The Company, through its majority
owned subsidiary OxyNet, Inc., is also currently engaged in the development and
commercialization of products incorporating a new ceramic-based technology for
separation of oxygen from ambient air and other gases. The first such product
targeted for commercialization is an oxygen concentrator for use in the home
health industry.
The Company was originally organized in 1989 for the purpose of
acquiring the exclusive territorial rights to market NSI's proprietary products
in Ohio. In 1990, it acquired from NSI marketing rights for Kentucky and the
Chicago, Illinois metropolitan area. On December 16, 1996, the Company completed
a merger with licensees that had held the rights to market the PAPNET Testing
System in the states of Missouri, Georgia and North Carolina. The Company was
the surviving corporation in the merger. Upon completion of the merger, the
Company changed its name from Papnet of Ohio, Inc. to NetMed, Inc.
As of the date of filing of this report, NSI is delinquent in the
payment to the Company of royalties due under the license agreement for the
months of January and February, 1999. On March 16, 1999, NSI announced that its
Netherlands subsidiary had commenced insolvency proceedings from creditors and
that NSI had discontinued operations in Germany. On March 26, 1999, NSI
announced that it had commenced reorganization proceedings under Chapter 11 of
the U.S. Bankruptcy Code. The Company is unable to predict or quantify the
impact that NSI's financial difficulties and bankruptcy reorganization may have
on the Company, but there is a substantial risk that they will have a material
adverse effect on the Company's business, results of operations and financial
condition.
NSI - LICENSOR OF THE PAPNET(R) TESTING SYSTEM
NSI, founded in 1988, is a healthcare technology company focused on
bringing intelligent vision to medicine. It is NSI's objective to become the
premier supplier of cytology screening and anatomic pathology diagnostic
equipment and services to laboratories. NSI's first, and to date, only product,
the PAPNET(R) Testing System, which has been reintroduced outside of the United
States under the brand name PAPNET-on-Cyte(TM), is a sophisticated interactive
system that assists the laboratory professional in the detection of abnormal
cells on cervical cytology specimens (also known as Pap smears).
Since its inception, NSI has been primarily engaged in the development,
manufacturing and marketing of the PAPNET Testing System, and the scanning of
Pap smears at its slide processing facilities. NSI's revenues are currently
being derived from sales of PAPNET testing services, sales of PAPNET Testing
Systems under the Papnet-on-Cyte(TM) trade name, laboratory services and
interest income.
THE PAPNET(R) TESTING SYSTEM
In the United States, the PAPNET Testing System is promoted to assist
the cytology professional in the examination of conventionally prepared smears
that have first been assessed by standard manual microscopy to be "negative,"
"within normal limits," or evidencing "benign cellular changes." Outside of the
United States, some of NSI's laboratory customers use the PAPNET Testing System
in a variety of different modes, including the assessment of Pap smears (both
conventional and liquid-based) that have not first been assessed by standard
manual microscopic review (an application known as "primary screening"). NSI
recently began marketing to laboratories in Europe and Asia a new version of the
PAPNET scanner, known as "PR1MA(TM)," that incorporates significant improvements
to the system's hardware and software and is optimized for use in the lab as a
primary screener.
The PAPNET Testing System was approved for commercial use in the United
States by the U. S. Food &
2
<PAGE> 3
Drug Administration ("FDA") on November 8, 1995. Currently, commercial use of
the PAPNET Testing System in the United States is limited by the FDA to the
rescreening of Pap smears that have been classified as "negative" for cervical
abnormality by manual microscopic inspection. In 1998, NSI announced its
intention to pursue FDA approval for use of the device as a primary screener in
the United States for both conventional and liquid-based Pap smears. NSI is
currently in the final stages of completing clinical trials that will form the
basis for an application for FDA approval of the primary screening application.
NSI has stated that it expects to file the application by the end of the second
quarter of 1999, and expects to receive FDA approval and to begin realizing
primary screening revenues in the U.S. by the end of 1999.
When used to supplement manual screening of Pap smears, PAPNET testing
has been shown to increase the detection of cervical abnormality by up to 30%
when compared to manual screening. The Company believes that this improved
detection can result in more effective and less costly early treatment, reduced
possibility of morbidity and mortality for patients, and reduced possibility of
malpractice litigation for the patient's doctor and laboratory. The PAPNET
Testing System can achieve these improvements without requiring a modification
of the standard Pap smear sample due to its use of a patented combination of
algorithmic and adaptive pattern recognition technology, a form of artificial
intelligence.
The PAPNET Testing System is a medical device subject to extensive
regulation in the United States by the FDA and other federal, state and local
authorities. The FDA regulates the research, development, clinical studies,
manufacturing, processing, packaging, labeling, distribution, promotion and
post-market surveillance of medical devices in the United States. The Company
relies entirely upon NSI to assure that all of these activities, as they relate
to the PAPNET Testing System, comply with all applicable regulatory
requirements.
THE CERVICAL CYTOLOGY MARKET
Pap smears are widely used in North America, Europe and other developed
areas to aid in the early detection of cervical cancer, and over 50 million
tests are performed annually in the U.S. alone. Pap smears can reveal early
changes in cervical cells that precede or indicate the development of cancer,
thereby facilitating timely medical intervention. When cervical cancer or
precancerous conditions are detected early on a Pap smear, the disease is almost
always completely curable using a simple outpatient procedure. However, if
abnormal cells on the Pap smear are not noticed by the laboratory, the patient
may be falsely told that her Pap smear is negative (a "false negative"), with
significant morbidity or mortality occurring as a result. Failure to diagnose
cervical cancer is a significant and rapidly growing source of malpractice
litigation against laboratories and clinicians in both the U.S.
and abroad.
Manual searching of routine Pap smears to spot abnormal cells is an
unavoidably tedious and error-prone task. This is primarily because a seriously
abnormal Pap smear can contain fewer than a dozen abnormal cells scattered among
hundreds of thousands of normal cells and other objects. The cytotechnologist's
job is thus very similar to proofreading a very long document to try to detect a
few misspelled words. Regardless of how conscientious and careful the laboratory
is, many of these "needles in a haystack" may be missed, and the patient falsely
informed that her Pap smear was negative. Manual screening false-negative rates
ranging from 10% to 40% have been reported in numerous published studies. The
PAPNET Testing System has been shown in several domestic and international
clinical studies published in peer-reviewed journals to detect abnormal cells on
Pap smears that were falsely diagnosed as "negative" by conventional manual
inspection.
The PAPNET Testing System is currently approved for use in the U. S.
only to rescreen Pap smears that have been previously examined microscopically
by a cytotechnologist and classified as "negative." Although several studies
have shown that use of the system in a rescreening mode is cost-effective (given
the reduced morbidity and mortality resulting from early detection of cervical
cancer), laboratories in the U.S. have been slow to implement PAPNET rescreening
due to the additional cost, and the lack of widespread insurance reimbursement.
The Company expects that if the primary screening primary application is
approved in the U.S., and marketing of NSI's new PR1MA system begins, it will be
able to demonstrate that use of the system as a primary screener will allow
laboratories to reduce their overall costs of screening Pap smears, while at the
same time improving the detection of cervical abnormalities.
COMPETITION IN THE CERVICAL CYTOLOGY MARKET
The Company is currently aware of four companies that are engaged in
efforts to automate one or more aspects of cervical smear screening. Three of
these, Cytyc, AutoCyte and MonoGen, have focused on the
3
<PAGE> 4
development of devices for the production, and in the case of AutoCyte,
automated analysis, of liquid-based (or "monolayer") slides, a potential
alternative to the conventional Pap smear method of specimen collection and
preparation. Cytyc received approval from the FDA in May 1996 to market its
ThinPrep(R) preparation to laboratories, for the purpose of filtering out blood,
mucus and other material from Pap smears. AutoCyte has submitted an application
to the FDA for premarketing approval of its monolayer method and scanning
process, but to date has not received FDA approval of either, although it
recently announced favorable FDA review of the clinical trial results for the
monolayer system. MonoGen's monolayer preparation method has been used for other
types of cytology specimens, but has not yet received FDA approval for use for
cervical cytology.
With monolayer techniques, clinicians are required to prepare special
slides, and only a portion of the cells and background information displayed on
the conventional slide is retained for analysis. Because these preparations
result in slides with fewer cells and less obscuring material, their
manufacturers claim an increased rate of detection of abnormal cells when the
slides are examined under a microscope. As opposed to the monolayer systems,
because the PAPNET System uses the conventional method of sample collection, it
does not require clinicians to deviate from standard practice in the preparation
or visual screening of Pap smears. NSI has included monolayer slides in its
recent clinical trials of the PAPNET System, and has stated that it intends to
seek FDA approval for primary screening of both conventional and monolayer
slides.
In July 1997, several persons (including Carl Genberg, a shareholder of
the Company and a director of NSI) filed a citizen's petition with the FDA
requesting that the FDA reexamine its earlier approval of the ThinPrep(R)
technology as a replacement for the conventional Pap smear. NSI and Cytyc were
also involved in litigation in which each asserted product disparagement claims
against the other, but in October, 1998, NSI announced that this litigation had
been settled.
NeoPath has received FDA approval for the use of its AutoPap(R) System
as part of a laboratory's quality control procedure. According to NeoPath, the
AutoPap System is designed to sort purportedly "negative" Pap smear slides into
two groups, one classified as "negative" and one classified for "review." The
group of slides classified for review, which constitutes a specified percentage
of the whole, is again reviewed manually by the cytotechnologist through a
conventional microscope. In 1998, NeoPath obtained FDA approval for partial
automated primary screening (as opposed to rescreening) of conventional Pap
smears, with certain limitations. NSI is currently engaged in litigation with
NeoPath alleging patent infringement, unfair competition and other tortious
conduct concerning the development and marketing of the AutoPap System. NeoPath
has denied these allegations and has asserted counterclaims to the effect that
NSI has made false and misleading representations concerning the AutoPap System.
NSI has stated that it believes NeoPath's assertions are without merit.
As noted above, the PAPNET Testing System has been successfully used as
a primary screener outside of the U.S. NSI has announced its intention to pursue
FDA approval for unrestricted use of the device as a primary screener in the
United States, and has stated that it views the recent panel recommendation
concerning the AutoPap System as a positive step toward eventual FDA approval of
the PAPNET System as a primary screener.
These or other competitors may develop new products and technologies
that prove to be more effective than the PAPNET Testing System or that may be
viewed by clinical laboratories as reducing operating costs (for example, by
reducing the number of cytotechnologists used in screening). In addition,
competitive products and technologies may be manufactured and marketed more
successfully than the PAPNET Testing System. Such developments could render the
PAPNET Testing System less competitive or possibly obsolete, and could have a
material adverse effect on NSI and the Company. NSI and the Company will be
required to compete with respect to product effectiveness, price, manufacturing
and slide processing efficiency, marketing capabilities and customer service and
support, areas in which they currently have limited experience.
In addition to competitors attempting to develop fully automated or
semi-automated systems for the screening or rescreening of cervical samples,
there may in the future be alternate techniques or technologies for the
detection or prevention of cervical cancer. Although no such technique has been
demonstrated to be useful as a substitute for the Pap smear, there can be no
assurance that new techniques or technologies will not one day supplant or
replace the Pap smear in medical practice.
The foregoing information concerning NSI and the PAPNET Testing System
was obtained either directly from NSI or from filings that NSI has made with the
Commission. While the Company believes that the foregoing information is
accurate and a fair summary of publicly available information concerning NSI and
the PAPNET Testing System, readers are encouraged to review NSI's filings with
the Securities and Exchange Commission for
4
<PAGE> 5
additional and more detailed information.
THE NSI LICENSES
The Company has the right and license to market the PAPNET Testing
System and service in the states of Ohio, Georgia, Kentucky, Missouri, North
Carolina and in the Chicago metropolitan area, representing approximately 16.5%
of the total U.S. population. The Company also has the right to market within
the licensed territory products developed by NSI from the PAPNET technology in
the future. The Company's rights are exclusive within the described territory,
subject to the right of NSI to conduct marketing and sales activities therein.
However, because the royalties paid to the Company are based on gross revenues
recognized by NSI from activities (including any sales by NSI) in the licensed
territory, any sales activities in the Company's territory by NSI will inure to
the benefit of the Company. The license expires on December 31, 2025, but is
renewable by the Company for an additional 20 year term upon payment to NSI of a
renewal fee equal to the net present value of twenty (20) years of annual
royalties at the average monthly rate payable in the twelve months immediately
preceding the date of the Company's election to renew.
Under the license, the Company is entitled to receive the greater of
(i) royalties equal to 50% of the net slide revenue generated from participating
laboratories within its territory, not to exceed the Company's share of revenues
from the first 9,736,735 slides annually; or (ii) 3.5% of NSI's annual slide
processing revenues less certain taxes, commissions and other enumerated
expenses, up to an annual aggregate limit of $18.3 million.
PAPNET(R) MARKETING
Following FDA approval of use of the PAPNET System for rescreening Pap
smears, NSI decided to focus its marketing of the product on primary care
physicians and consumers. It deployed a sales force to call on individual
physicians and group practices, and developed point of sale brochures and a
national advertising campaign to communicate directly to consumers the benefits
of PAPNET rescreening. After evaluating the costs and results of this approach,
in late 1997 NSI decided to refocus its marketing efforts on laboratories, and
offered pricing concessions to laboratories that agreed to rescreen 100% of
their negative Pap smears with the PAPNET System. The first two laboratories
implementing this program are located in the Company's licensed territory. At
about the same time, NSI reevaluated its strategy of positioning the PAPNET
System as a rescreener of manually screened Pap smears, and decided to pursue
FDA approval of use of the system as a primary screener of both conventional and
monolayer slides. As a result of these changes, in 1998 the Company redirected
its marketing efforts toward pursuing 100% rescreening and other volume-priced
transactions with laboratories and obtaining insurance and managed care coverage
for the PAPNET test, pending FDA approval of use of the PAPNET System as a
primary screener.
THIRD-PARTY PAPNET(R) REIMBURSEMENT
The lack of adequate and widespread reimbursement of laboratory charges
for PAPNET testing by third-party medical insurance payers, managed care
organizations, and government agencies (such as Medicare/Medicaid, private
health insurance, health maintenance organizations and self-insured employers)
has been a key factor in limiting the rate of growth of the revenues which NSI
and the Company have to date been able to realize from this technology.
Currently, while some third-party payers in the U.S. reimburse some or all of
the charges to patients for PAPNET rescreening, many others (including Medicare,
and in most states, Medicaid) provide little or no reimbursement. As a result,
the size of the U.S. market for PAPNET rescreening has been substantially
smaller than originally anticipated by NSI and the Company, and this has been a
significant factor in causing NSI to focus its efforts on obtaining FDA approval
for primary screening in the U.S. Because of the significant economies that the
Company expects laboratories will realize from use of the PAPNET system as a
primary screener, the availability of additional third-party reimbursement for
the test (i.e., over and above the currently prevailing levels of reimbursement
for Pap smears) is not expected to be as substantial an impediment to market
acceptance.
OXYGEN TECHNOLOGY
In early 1997, the Company entered into an agreement with CeramPhysics,
Inc. of Westerville, Ohio ("Ceram"), pursuant to which the Company obtained the
right to acquire 95% ownership of Ceram Oxygen Technologies, Inc. ("COTI"), a
Ceram subsidiary that holds an exclusive world-wide license to Ceram's patented
ceramic oxygen generation technology for all applications of the technology
except oxygen sensors and fuel cells. On April 3, 1998, the Company acquired
from COTI 95 common shares, representing 95 percent of COTI's outstanding common
shares, in exchange for a cash payment of $50,000 and delivery of a note in the
principal
5
<PAGE> 6
amount of $150,000. The note provided for three equal principal payments of
$50,000 on each of June 1, July 1, and August 1, 1998, together with interest at
the rate of 8.5 percent per annum. The cash payment and note were assigned by
COTI to Ceram in payment of a $200,000 license fee for the technology. Following
this transaction, COTI's name was changed to "OxyNet, Inc."
It is the Company's intention to incorporate the technology into
products that separate and concentrate oxygen from ambient air and other gases,
with the first product being a lightweight oxygen concentrator for use in the
home health industry. Since acquisition of the rights to the technology, the
Company has proceeded with the scale-up of early demonstration modules
incorporating the technology, and has developed other components necessary to
construct a prototype oxygen concentrator system. Although the Company has
experienced technical challenges that have delayed the completion of a
prototype, the Company now expects to complete and demonstrate the prototype in
April, 1999.
Assuming successful completion of the prototype, it is the Company's
intention to proceed with the development of a commercial version of the device,
obtain appropriate regulatory approvals, and commence manufacturing, marketing
and distribution of the product. These activities are likely to require
substantial expenditures in 1999 and subsequent years, requiring it to seek
additional capital during this period. The amount and timing of the Company's
capital needs will depend to a large degree upon the ultimate methods of
manufacture, marketing and distribution chosen by the Company. The Company is
currently pursuing negotiations with companies in the oxygen and gas separation
business that may result in the Company entering into a licensing, joint venture
or similar relationship to commercialize the product and to develop military and
industrial applications.
The Company is currently engaged in litigation with Ceram and its
principals over a purported termination of the license for this technology, as
well as disputes concerning the scope of the license and the payment of
royalties. See "Legal Proceedings."
PERSONNEL
As of March 15, 1999, the Company employed three full time employees,
and one part time employee. None of the Company's employees are subject to a
collective bargaining agreement, and the Company considers its relationship with
its employees to be good. The Company supplements its staff through ongoing
consulting arrangements with several persons and organizations, which provide
additional technical and marketing advisory services to the Company on an
as-needed basis.
BUSINESS RISKS
The Private Securities Litigation Reform Act of 1995 provides a "safe
harbor" for certain forward-looking statements. The following factors, among
others, could cause actual results to differ materially from those contained in
forward-looking statements made in this report, including without limitation,
the sections entitled "Business," "Management's Discussion and Analysis of
Financial Condition and Results of Operations" and "Legal Proceedings." When
used in this report and the documents incorporated by reference herein, the
words "estimate," "project," "anticipate," "expect," "believe" and words of
similar import are intended to identify forward-looking statements.
OUR DEPENDENCE ON NEUROMEDICAL SYSTEMS, INC. COULD ADVERSELY EFFECT OUR ABILITY
TO SUCCESSFULLY MARKET THE TECHNOLOGY WE SELL
While Neuromedical Systems has granted us exclusive rights with respect
to the marketing of the PAPNET Testing System and service in some geographic
territories, we have no ownership rights in the PAPNET technology. Our PAPNET
business is dependent upon a number of factors, many of which are controlled by
Neuromedical Systems. These factors include:
o maintaining the PAPNET Testing System's compliance with FDA and other
regulatory requirements
o maintenance of the technological advantages of the PAPNET Testing
System
o maintenance of product liability insurance
o the ability to manufacture and deliver the equipment required to
operate the PAPNET Testing System
6
<PAGE> 7
We obtain all of the information relating to the PAPNET Testing System
and service from Neuromedical Systems, and in most cases cannot independently
verify this information. Therefore, we are dependent on Neuromedical Systems to
accurately report the results of clinical studies and other data relating to the
capabilities and performance of the PAPNET Testing System.
FINANCIAL PROBLEMS AT NEUROMEDICAL SYSTEMS COULD HAVE AN ADVERSE EFFECT ON OUR
LICENSE AND OUR BUSINESS
As of the date of filing of this report, NSI is delinquent in the
payment to the Company of royalties due under the license agreement for the
months of January and February, 1999. On March 16, 1999, NSI announced that its
Netherlands subsidiary had commenced insolvency proceedings from creditors and
that NSI had discontinued operations in Germany. On March 26, 1999, NSI
announced that it had commenced reorganization proceedings under Chapter 11 of
the U.S. Bankruptcy Code. From this and other available information, the Company
believes that there is a substantial risk that NSI may not have sufficient
financial resources to remain in business. The Company is unable to predict or
quantify the impact that NSI's financial difficulties and bankruptcy
reorganization may have on the Company, but there is a substantial risk that
they will have a material adverse effect on the Company's business, results of
operations and financial condition.
Additional risks relating to the business of NSI which may have an
impact on us are set forth in NSI's periodic reports filed with the SEC,
including its Annual Report on Form 10-K.
OUR LICENSE AGREEMENTS MAY LIMIT OUR POTENTIAL FOR GROWTH
Our marketing rights for the PAPNET Testing System and the revenues
generated by these activities are governed by the terms of our license from
Neuromedical Systems. The license imposes significant territorial and other
restrictions on our marketing rights. These restrictions may limit our potential
for growth and our ability to attract new customers.
WE MAY BE UNABLE TO CONTINUE AS A GOING CONCERN
We have to date had limited income from operations, and as of December
31, 1998 have accumulated recurring losses of $6,724,384. We have recently
experienced declining revenues from the marketing of the PAPNET Testing System,
and we currently do not have adequate funds to complete development and
commercialization of our OxyNet oxygen concentrator. Until a successful
commercial launch of the oxygen product (which is not assured) we will be
dependent upon the successful marketing of the PAPNET System for revenues. These
factors raise substantial doubt as to our ability to continue in business.
WE NEED TO RAISE ADDITIONAL CAPITAL IN 1999 IN ORDER TO BE SUCCESSFUL
We will likely incur substantial expenditures during 1999 to complete
development and commercialization of the OxyNet oxygen concentrator. We do not
currently have adequate funds to accomplish this objective, and anticipate that
we may need to raise additional capital in 1999. We are unsure whether capital
will be available at that time.
ISSUANCE OF ADDITIONAL EQUITY SECURITIES COULD DILUTE YOUR INTEREST
Terms of our preferred shares issued by an OxyNet subsidiary include
the right to exchange these for our common stock. This may have a dilutive
effect on our common shareholders. See "Market For Common Equity And Related
Stockholder Matters."
If we issue equity securities to raise funds, each current
shareholder's interest may be reduced. Further, such equity securities may have
rights, preferences or privileges senior to the common shares.
BECAUSE WE DO NOT PLAN ON PAYING ANY DIVIDENDS, THE ONLY BENEFIT YOU CAN RECEIVE
FROM OWNING OUR STOCK IS THROUGH APPRECIATION OF THE STOCK'S VALUE
We have not paid and do not anticipate paying any cash dividends in the
foreseeable future. If we do not pay dividends, the only way you can benefit
from owning our stock is through appreciation of the stock's value. We intend to
retain future earnings for the development and expansion of our business. We
have accumulated
7
<PAGE> 8
substantial losses since our inception. There can be no assurance that our
operations will result in sufficient revenues to enable us to operate at
profitable levels or to generate positive cash flow.
THE CONCENTRATION OF OWNERSHIP OF THE COMMON SHARES MAY LIMIT YOUR ABILITY TO
INFLUENCE MATTERS
Our directors, executive officers and principal shareholders (5% or
greater) collectively beneficially own or have the right to acquire under
currently exercisable options approximately 20% of the outstanding common
shares. As a result, these shareholders will be able to exercise significant
influence over matters requiring shareholder approval, including the election of
directors and approval of significant corporate transactions. Such concentration
of ownership may have the effect of delaying or preventing a change in control.
We had 11,987,605 common shares outstanding as of December 31, 1998.
Approximately 1,925,000 shares are held by affiliates of NetMed who will be
entitled to resell them only pursuant to a registration statement under the
Securities Act of 1933 or an applicable exemption from registration. In August
1997, we sold $3 million in principal amount of debentures convertible into
common shares at a discount to the market price at the time of conversion. The
debentures that were not converted into common stock were exchanged for
preferred stock on January 22, 1999. If the $1,467,619 in stated value of the
preferred stock issued in the exchange were converted at the prevailing market
price on that date approximately 7,827,000 additional shares of common stock
would be issued. We have agreed to take certain actions to permit resale of the
balance of the common shares that may be issued on conversion of the preferred
stock. Such resales may adversely affect the pricing and volatility of trading
in the common shares.
POSSIBLE DELISTING OF OUR SHARES FROM THE AMERICAN STOCK EXCHANGE
Although the common shares are currently listed for trading on the
American Stock Exchange, trading volume has been limited. There can be no
assurance that there will continue to be an active and liquid trading market.
The stock market has experienced extreme price and volume fluctuations and
volatility that has particularly affected the market prices of many technology,
emerging growth and developmental stage companies. Such fluctuations and
volatility have often been unrelated or disproportionate to the operating
performance of such companies. Factors such as announcements of the introduction
of new or enhanced services or related products by us or our competitors may
have a significant impact on the market price of the common shares.
In August 1998, the staff of the American Stock Exchange recommended
that the common shares be delisted from trading on the Exchange because of our
failure to meet minimum financial requirements for continued listing. We
appealed this determination to the Board of Governors of the Exchange, which
permitted our continued listing on the Exchange until March 31, 1999, when the
listing will be reviewed again. If the common shares are delisted, it is likely
that the common shares will be quoted on the National Association of Securities
Dealers, Inc. (Nasdaq) Bulletin Board.
VOLATILITY OF MEDICAL TECHNOLOGY COMPANIES' SECURITIES MAY ADVERSELY EFFECT THE
MARKET PRICE OF YOUR STOCK
Market prices of securities of medical technology companies, including
our common shares, have experienced significant volatility from time to time.
There may be volatility in the market price of our common shares due to factors
that may not relate to our performance. Various factors and events, such as
announcements by us or our competitors concerning new product developments,
governmental approvals, regulations or actions, developments or disputes
relating to patent or proprietary rights and public concern over product
liability may have a significant impact on the market price of our common
shares.
A LOW STOCK PRICE MAY TRIGGER THE PENNY STOCK RULES MAKING IT HARDER FOR BROKERS
TO SELL YOUR STOCK
If the Exchange delists our common shares, trading in the shares could
become subject to Rule 15g-9 under the Securities Exchange Act of 1934. This
rule imposes additional sales practice requirements on broker-dealers who sell
so-called "penny" stocks to persons other than established customers and
"accredited investors." Generally, accredited investors are individuals with a
net worth of more than $1,000,000 or annual incomes exceeding $200,000, or
$300,000 together with their spouses. For transactions covered by this rule, a
broker-dealer must make a special suitability determination for the purchaser
and have received the purchaser's written consent to the transaction before
sale. Consequently, the rule may adversely affect the ability of broker-dealers
to sell our shares in the secondary market.
8
<PAGE> 9
Subject to some exceptions, the Commission's regulations define a
"penny stock" to be any non-exchange listed equity security that has a market
price of less than $5.00 per share, or with an exercise price of less than $5.00
per share. Unless exempt, the rules require delivery, prior to any transaction
in a penny stock, of a disclosure schedule relating to the penny stock market
and the associated risks. The rules also require disclosure about commissions
payable to both the broker-dealer and the registered representative and current
quotations for the securities. Finally, the rules require that broker-dealers
send monthly statements disclosing recent price information for the penny stock
held in the account and information on the limited market in penny stocks.
If our common shares became subject to the rules applicable to penny
stocks, the market liquidity for our common shares could be adversely affected.
GOVERNMENT REGULATION OF OUR SERVICES CAN SLOW DOWN OR IMPEDE OUR ABILITY TO
SELL OUR EXISTING OR NEW SERVICES
Both our and Neuromedical Systems' services, products and manufacturing
activities are subject to extensive and rigorous government regulation,
including the provisions of the Medical Device Amendment to the Federal Food,
Drug and Cosmetic Act. Sales to some foreign countries are also subject to
government regulations. Failure to comply with applicable regulatory
requirements can result in fines, suspensions of approvals, seizures or recalls
of products, operating restrictions and criminal prosecutions. Furthermore,
changes in existing regulations or adoption of new regulations could prevent us
or Neuromedical Systems from obtaining, or affect the timing of, future
regulatory approvals. The effect of governmental regulation may be to delay for
a considerable period of time or to prevent the marketing and/or full
commercialization of future products or services that we or Neuromedical Systems
may develop and/or impose costly requirements on us or Neuromedical Systems.
The process of obtaining required regulatory approvals can be lengthy,
expensive and uncertain. Moreover, regulatory approvals, if granted, may include
significant limitations on the indicated uses for which a product may be
marketed. The FDA actively enforces regulations prohibiting marketing without
compliance with the premarket approval provisions of products and conducts
periodic inspections to determine compliance with Good Manufacturing Practice
regulations. There can be no assurance that either we or Neuromedical Systems
will be able to obtain regulatory approvals of any products on a timely basis or
at all. Delays in receipt of or failure to receive such approvals or loss of
previously received approvals would adversely affect the marketing of
Neuromedical Systems' and our proposed products. There can also be no assurance
that additional regulations will not be adopted or current regulations amended
in such a manner as will materially adversely effect Neuromedical Systems or
NetMed.
THIRD PARTY REIMBURSEMENT FOR OUR SERVICES MAY AFFECT THE PRICING AND
ATTRACTIVENESS OF OUR SERVICES
In the United States, many Pap smears are currently paid for by the
patient. Further, the level of reimbursement by third-party payers that do
provide reimbursement differ considerably. Third-party payers, such as,
Medicare/Medicaid, private health insurance, health maintenance organizations,
health administration authorities in foreign countries and other organizations
may affect the pricing or relative attractiveness of our products and services
by regulating the maximum amount of reimbursement for products or services
provided by us or by not providing any reimbursement at all. Restrictions on
reimbursement may limit the price which we can charge for our products and
services or reduce the demand for them. In the case of PAPNET testing, if the
level of such reimbursement is significantly below what laboratories charge
patients to perform the test, the size of the potential market available to us
may be reduced. There can be no assurance of the extent to which costs of PAPNET
testing will become reimbursable or that the level of reimbursement will be
sufficient to permit us to generate substantial revenues in our PAPNET business.
THE LOSS OF PATENTS OR CONFIDENTIAL INFORMATION WOULD ADVERSELY EFFECT OUR
ABILITY TO COMPETE WITH THIRD PARTIES
The technologies underlying the PAPNET System and the OxyNet oxygen
concentrator are protected by various patents. There can be no assurance that
these patents will afford protection from material infringement by third parties
or that such patents will not be challenged. We and Neuromedical Systems also
rely on trade secrets and proprietary know-how, which we seek to protect, in
part, through confidentiality agreements with employees, consultants and other
parties. All of our employees, with the exception of clerical employees, are
required to sign a confidentiality agreement with us. To date, all employees
required to sign confidentiality agreements have done so.
9
<PAGE> 10
There can be no assurance that these agreements will not be breached, that there
will be adequate remedies for any breach or that our trade secrets will not
otherwise become known to, or independently developed by, competitors.
Litigation is currently pending between Neuromedical Systems and a competitor
over alleged infringement of Neuromedical Systems' patents.
There has been extensive litigation in the medical device industry
regarding patents and other intellectual property rights. Although patent and
intellectual property disputes in the medical device area have often been
settled through licensing or similar arrangements, costs associated with such
arrangements may be substantial. There can be no assurance that necessary
licenses would be available to Neuromedical Systems or us on satisfactory terms
or at all. Adverse determinations as to the PAPNET and OxyNet patents could:
o limit or destroy the value of our license rights to these technologies
o subject us to significant liabilities from third parties
o require us to seek licenses from third parties
o prevent us from manufacturing or selling these products
Any of these determinations could have a material adverse effect on our
business, financial condition and results of operations.
WE ARE DEPENDENT UPON THE SALE OF THE PAPNET SYSTEM AND ANY DIFFICULTIES WE HAVE
IN SELLING OUR PRODUCT COULD ADVERSELY EFFECT OUR BUSINESS
Until successful completion and sale of the OxyNet system, if ever, our
performance will depend upon sale of the PAPNET System. The extent of, and rate
at which, market acceptance and penetration are achieved are functions of many
variables including, but not limited to:
o price
o effectiveness
o acceptance by patients, physicians and laboratories
o manufacturing
o slide processing and training capacity
o reimbursement practice
o marketing and sales efforts
There can be no assurance that the PAPNET System will achieve or maintain
acceptance in our target markets.
INTENSE COMPETITION FROM DEVELOPING SYSTEMS COULD CAUSE US TO LOSE MARKET SHARE
We are aware of several companies that either have developed or are
developing systems that are competitive with the PAPNET System and other
technologies targeted for development by us. The sale of such products could
have a material adverse effect on our business, financial condition and results
of operations. Competitors may have substantially greater financial,
manufacturing, marketing and technical resources, and represent significant
potential long-term competition. Competitors may succeed in developing products
that are more effective or less costly than any that may be developed by
Neuromedical Systems or us. New developments are expected to continue at a rapid
pace in both industry and academia. There can be no assurance that research and
development by others will not render Neuromedical Systems' or our current and
contemplated products obsolete. Competition may increase further as a result of
advances that may be made in the commercial applicability of technologies and
greater availability of capital for investment in these fields.
FAILURE OR INACCURACY OF THE PAPNET SYSTEM COULD LEAD TO PRODUCT LIABILITY
Our business could expose us to the risks inherent in the production
and distribution of medical diagnostic and treatment equipment. Although
Neuromedical Systems has attempted to reduce the exposure to product liability
risk by disclosing the demonstrated range of accuracy of the PAPNET Testing
System, there can be no assurance that we will not be exposed to liability
resulting from the failure or inaccuracy of the PAPNET System. We currently
carry no product liability insurance. However, Neuromedical Systems is required,
under the terms of the Licenses, to name us as an additional insured on its
product liability policies. There can be no assurance that Neuromedical Systems
will have the resources necessary to purchase and maintain the insurance, that
such insurance will be
10
<PAGE> 11
sufficient to cover potential claims, or that Neuromedical Systems will have
adequate resources to indemnify us from any uninsured loss.
ITEM 2. PROPERTIES.
The Company's executive offices are located in Dublin, Ohio,
in approximately 4,900 square feet of space. The Company leases such space at an
annual net rent of $53,900.
ITEM 3. LEGAL PROCEEDINGS.
On March 1, 1999, the Company and OxyNet commenced a lawsuit in the
Common Pleas Court of Franklin County, Ohio against Ceram and its principals
over a purported termination of the license for the ceramic oxygen generation
technology, as well as over other disputes, including whether oxygen "scrubbing"
applications are included in the scope of the license and whether minimum
royalties are payable prior to the manufacture or sale of products incorporating
the technology. On March 3, 1999, the Company and OxyNet obtained a temporary
restraining order prohibiting Ceram from taking any action to terminate the
license or that otherwise is inconsistent with the rights of the Company and
Ceram under the license. On March 24, 1999, the court issued a decision finding
that the license had not been terminated and granting a preliminary and
permanent injunction against Ceram from taking any action inconsistent with the
Company's rights under the license. While the Company is confident that it will
prevail in any appeal from that decision, and that its other claims will be
found meritorious, it is unable to predict the ultimate outcome of the
litigation.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
Not applicable.
PART II
ITEM 5. MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS.
The Common Shares are listed for trading on the American Stock Exchange
under the symbol "NMD." The following table sets forth, for the periods
indicated, the high and low last sales prices per share, as reported on the
American Stock Exchange.
<TABLE>
<S> <C> <C>
First Quarter 1997............................. $ 9.625 $ 6.625
Second Quarter 1997............................ 7.875 5.00
Third Quarter 1997............................. 6.875 4.00
Fourth Quarter 1997............................ 4.50 2.063
First Quarter 1998............................. $ 2.4375 $ 0.9375
Second Quarter 1998............................ 1.25 0.625
Third Quarter 1998............................. 0.8438 0.0625
Fourth Quarter 1998............................ 0.5625 0.1875
</TABLE>
On March 26, 1999, the last reported sale price of the Common Shares
was $0.125 per share. On March 1, 1999, there were 406 holders of record of the
Common Shares.
The Company has not paid and does not anticipate paying any cash
dividends in the foreseeable future and intends to retain future earnings for
the development and expansion of its business. Any future determination to pay
dividends will be at the discretion of the Board and subject to certain
limitations under the Ohio General Corporation Law and will depend upon the
Company's results of operations, financial condition, contractual restrictions
and other factors deemed relevant by the Board.
11
<PAGE> 12
In August, 1998, the Company's OxyNet subsidiary completed the private
placement of 500 Series A 8% Convertible Preferred Shares for net proceeds of
$491,000. These proceeds have been and will continue be used for further
development of products incorporating OxyNet's ceramic oxygen generation
technology. The OxyNet preferred shares are convertible into common shares of
OxyNet on a one share for one share basis. If there is not an initial public
offering of the common shares of OxyNet within 18 months from the date of
issuance of the OxyNet shares, the OxyNet shares may be exchanged at their
original stated value, plus accrued dividends, for NetMed common shares. This
is a one time right to exchange the OxyNet shares for NetMed common shares and
is only available for a period of 30 days following the expiration of the 18
month period referenced above. The exercise of these exchange rights may
result in further dilution to holders of the NetMed's common shares.
ITEM 6. SELECTED FINANCIAL DATA.
Year ended December 31,
<TABLE>
<CAPTION>
1994 1995 1996 1997(1) 1998(1)
------------ ----------- ------------- ------------ -----------
<S> <C> <C> <C> <C> <C>
Revenue $ 24,765 $ 48,000 $ 102,813 $ 893,608 $ 399,848
Loss from operations (302,596) (525,149) (1,677,312) (2,453,599) (1,568,898)
Net income (loss) (283,537) 1,324,945 (592,822) (3,284,276) (2,638,806)
Net income (loss)
per share - Basic (0.05) 0.22 (0.09) (0.30) (.23)
Diluted (0.05) 0.21 (0.09) (0.30) (.23)
BALANCE SHEET DATA:
Total assets 768,934 9,225,744 10,379,590 3,769,049 1,472,195
Convertible
Debentures - - - 2,190,000 1,350,000
Total Shareholders'
equity 738,600 6,253,679 7,035,067 832,095 (900,677)
</TABLE>
(1) The Company's financial statements from which this data are selected are
subject to a qualified auditors' opinion. See Item 8 - "Financial
Statements and Supplementary Data."
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS.
OVERVIEW
The Company is engaged in the business of acquiring, developing and
marketing medical and health-related technologies. The Company's principal
business activity is the marketing of the PAPNET(R) Testing System under
license from NSI. The Company, through its majority owned subsidiary OxyNet,
Inc., is also currently engaged in the development and commercialization of
products incorporating a new ceramic-based technology for separation of oxygen
from ambient air and other gases. The first such product targeted for
commercialization is an oxygen concentrator for use in the home health
industry.
Total revenue decreased approximately 55 percent for the twelve months
ended December 31, 1998 compared to the same period last year. The decrease is
directly attributable to the shift in NSI's marketing focus for the PAPNET
product in the U.S. away from rescreening. While further decreases in revenue
attributable to the rescreening business in the U.S. are possible, the
Company's license agreement with NSI provides for a minimum royalty of 3.5% of
NSI's worldwide revenue. The Company's recurring losses, decreasing revenues,
and net capital deficiency raise substantial doubt about its ability to
continue as a going concern, and the report of the Company's independent
auditors on the financial statements included in this report contains a
qualification to that effect.
As of the date of filing of this report, NSI is delinquent in the payment
to the Company of royalties due
12
<PAGE> 13
under the license agreement for the months of January and February, 1999. On
March 16, 1999, NSI announced that its Netherlands subsidiary had commenced
insolvency proceedings from creditors and that NSI had discontinued operations
in Germany. On March 26, 1999, NSI announced that it had commenced
reorganization proceedings under Chapter 11 of the U.S. Bankruptcy Code. The
Company is unable to predict or quantify the impact that NSI's financial
difficulties and bankruptcy reorganization may have on the Company, but there
is a substantial risk that they will have a material adverse effect on the
Company's business, results of operations and financial condition.
On April 3, 1998, the Company acquired 95% ownership of Ceram Oxygen
Technologies, Inc. (see Note 5 to financial statements) and changed the name to
OxyNet, Inc. ("OxyNet"). The development by OxyNet of an oxygen concentrator
for use in the home healthcare market continued during 1998.
In August 1998, OxyNet completed the sale of 500 convertible preferred
shares with net proceeds to OxyNet of $491,000. Proceeds of the offering are
to be used as further funding of the oxygen development project (see Note 11 to
the financial statements).
On December 16, 1996, the Company completed a merger with licensees that
had held the rights to market the PAPNET Testing System in the states of
Missouri, Georgia and North Carolina. For accounting purposes, the historical
financial statements of the Company prior to December 16, 1996 are those of its
predecessor, Papnet of Ohio, Inc. The results of operations for the merged
entities are reported on a prospective basis commencing December 16, 1996.
This report contains forward-looking statements that involve risks and
uncertainties. The Company's actual results may differ materially from the
results discussed in the forward-looking statements. Factors that might cause
such a difference include, but are not limited to, those discussed in Item 1 of
this report, in the section titled "Business Risks."
RESULTS OF OPERATIONS
TWELVE MONTHS ENDED DECEMBER 31, 1998 AND 1997
Royalty revenue decreased from $894,000 for the twelve months ended
December 31, 1997 to $400,000 for the twelve months ended December 31, 1998.
The decrease was due to a volume decrease of 29% for the twelve month period
and by a lower average price per test due to the special pricing offered to
laboratories for 100% PAPNET rescreening.
Total operating expenses decreased by 41% from $3,347,000 for the twelve
months ended December 31, 1997 to $1,969,000 for the same period in 1998.
Business development expenses increased $106,000 as the Company continued the
development and testing of the OxyNeta ceramic oxygen generator. Selling,
general and administrative expense decreased from $3,053,000 to $1,569,000
primarily due to a decrease in sales and marketing expenses of $840,000 caused
by a reduction in the sales force and by the elimination of recruiting fees and
lower supplies cost as the Company transitioned its marketing focus to the
laboratory from the clinician office. In addition, advertising expense
decreased by $120,000. General and administrative expense decreased $644,000
primarily as the result of a decrease in employee cost and professional fees.
In August 1997, the Company completed a $3,000,000 convertible debenture
financing. The Company recorded an additional $100,000 of finance expense in
1998 to reflect the amortization of the remaining discount on the debentures.
As security for the debentures, the Company pledged shares of NSI common stock
owned by the Company, and under certain conditions the holders had the right to
convert outstanding principle and interest on the debentures into the right to
receive pledged shares. For the twelve months ended December 31, 1998, the
purchasers converted $475,000 of principal plus accrued interest into a total
of 352,200 shares of NSI. This resulted in a loss on available for sale
securities of $894,000 for the twelve months ended December 31, 1998. For the
twelve months ended December 31, 1997 the Company sold 246,000 shares of
available for sale securities in order to fund operations and recognized a gain
of $795,000. On January 22, 1999, the holders of the outstanding debentures
agreed to exchange them for 97,712 shares of Series A 6% Convertible Preferred
Stock of the Company.
Interest income increased from $39,000 for the twelve months ended
December 31, 1997 to $41,000 for the twelve months ended December 31, 1998.
The increase is due to higher cash balances to invest as a result of a
convertible debenture financing completed in August 1997.
13
<PAGE> 14
Interest expense increased from $72,000 for the twelve months ended
December 31, 1997 to $104,000 for the same period in 1998. The increase in
interest expense is the result of the convertible debenture financing mentioned
above.
TWELVE MONTHS ENDED DECEMBER 31, 1997 AND 1996
Royalty revenue increased to $894,000 for the year ended December 31, 1997
from $103,000 for the year ended December 31, 1996. The increase can be
attributed to an increase in market penetration due to an increased sales force
calling on doctors and laboratories, consumer advertising and increased
insurance reimbursement during 1997 compared to 1996.
Total operating expenses increased to $3,347,000 for the twelve months
ended December 31, 1997 from $1,780,000 for the same period in 1996. Business
development expenses increased $209,000 as the Company continued the
development and testing of the OxyNeta ceramic oxygen generator. Selling,
general and administrative expense increased to $3,053,000 from $1,330,000
primarily due to the direct costs associated with the increased number of sales
representatives, an increase in sales literature and promotional materials used
in physician offices and an increase in advertising.
General and administrative expenses increased to $613,000 for the year
ended December 31, 1997 from $241,000 for the year ended December 31, 1996.
Approximately $200,000 of the increase is due to increased professional fees
associated with being a publicly traded company listed on a national exchange,
including legal, accounting and investor relations activities. The remaining
increase is due to the increased administrative headcount, an increase in
occupancy costs as a result of increased office space and an increase in
insurance costs associated with the purchase of directors and officers
liability insurance.
For the year ended December 31, 1996, the Company incurred one time merger
expenses of $364,852. No expenses related to this transaction were incurred in
1997.
The Company issued $3,000,000 in principal amount of 6% Secured
Convertible Subordinated Debentures ("Debentures") on August 13, 1997, and
recorded associated expenses of $1,106,452. The expenses included $750,000,
representing the 1997 portion of the discount, $100,000 for the value of
warrants issued to placement agents and the purchasers of the Debentures,
$170,000 in placement fees and $87,000 in professional, stock exchange and
registration fees associated with the Debentures and subsequent registration
statement. (See Note 4 to the Financial Statements.)
Interest income was $39,442 for the year ended December 31, 1997 compared
to $13,743 for the year ended December 31, 1996. The increase is due to
increased cash balances available for investment resulting from the net
proceeds of the Debentures.
Interest expense increased to $72,464 for the year ended December 31, 1997
compared to $872 for the year ended December 31, 1996. The increase in the
expense is the result of borrowings through margin accounts utilizing NSI
common stock for collateral and the expense associated with the Debentures.
The Company recognized a gain on available-for-sale securities of $794,819
for the year ended December 31, 1997 compared to $664,057 for the same period
in 1996 which has been recorded as other income.
The equity in income or loss in partnerships is the Company's percentage
of income or loss in certain predecessor limited partnerships that were merged
into the Company effective December 16, 1996.
LIQUIDITY AND CAPITAL RESOURCES
The Company has financed its operations to date primarily by receipt of
royalty payments from NSI, the sale of NSI common stock owned by the Company,
the sale of common shares, the sale of preferred stock of its OxyNet
subsidiary, and the sale of the convertible debentures. The Company's combined
cash and cash equivalents totaled $514,000 at December 31, 1998, a decrease of
$1,143,000 from December 31, 1997.
Cash used in the Company's operations was $1,403,000 for the twelve months
ended December 31, 1998 versus $2,308,000 used in the same period of 1997. The
Company anticipates that its cash requirements will be substantial for the
immediate future and believes that it will be necessary to obtain additional
funding in order to
14
<PAGE> 15
complete the development of the OxyNet device and continue funding the negative
cash flow from operations. In April 1998, the Company completed the previously
announced transaction with Ceram to acquire 95% ownership of a Ceram subsidiary
(now known as OxyNet, Inc.) that holds an exclusive world-wide license to
Ceram's patented oxygen generation technology for all applications except
oxygen sensors and fuel cells. The Company anticipates incurring significant
expenses to complete the development of an oxygen device with an anticipated
commercial product launch to the home healthcare market during the year 2000.
In August 1998, OxyNet completed the sale of 500 8% Cumulative Convertible
Preferred shares (the "Shares") in a private placement, with net proceeds to
OxyNet of $491,000. The Shares are entitled to cumulative dividends at the
rate of 8% per annum, and are convertible into common shares of OxyNet, Inc. on
a one share for one share basis (subject to adjustments for dilution in certain
events). The Shares were sold with a one time right to exchange them at their
original stated value, plus accrued dividends, for common shares of NetMed for
a period of 30 days following a date which is 18 months from the date of
issuance, at the then-prevailing market price of NetMed common shares (not to
exceed $3.00 per share), if there has been no initial public offering for
common shares of OxyNet by such date. NetMed is the parent of OxyNet and would
own approximately 89.1% of OxyNet's outstanding common stock on a fully
converted basis if the preferred shares are exchanged for OxyNet common shares.
The Company believes that the net proceeds of $491,000 from the private
placement will be sufficient for the development of a prototype oxygen device,
but that additional financing will be required to obtain the necessary U.S.
regulatory approvals and to complete the commercial launch of a product
incorporating this technology.
The Company has reduced expenses as a result of focusing the sales and
marketing efforts of the PAPNET test towards the laboratory and away from the
clinician, by reducing other general and administrative headcount and by
substantially reducing the cash compensation paid to certain officers.
Beginning in the third quarter of 1998, cash compensation of certain officers
was discontinued until such time as the Company's Board of Directors is
satisfied that the Company has the ability to fund operations from either
internal or external sources.
The Company's future liquidity and capital requirements will depend upon
numerous factors, including the resources required to further develop the
OxyNet oxygen device, the success of laboratory marketing plans and the
Company's ability to increase the sales of the PAPNET Testing System, the
timing of NSI's receipt of FDA approval for the PAPNET Testing System as a
primary screener of all cytological specimens and the resources required to
manufacture and market the OxyNet device. Additional funding may not be
available when needed or on terms acceptable to the Company, which would have a
material adverse effect on the Company's business, financial condition, and
results of operations.
As of the date of filing of this report, NSI is delinquent in the payment
to the Company of royalties due under the license agreement for the months of
January and February, 1999. On March 16, 1999, NSI announced that its
Netherlands subsidiary had commenced insolvency proceedings from creditors and
that NSI had discontinued operations in Germany. On March 26, 1999, NSI
announced that it had commenced reorganization proceedings under Chapter 11 of
the U.S. Bankruptcy Code. The Company is unable to predict or quantify the
impact that NSI's financial difficulties and bankruptcy reorganization may have
on the Company, but there is a substantial risk that they will have a material
adverse effect on the Company's business, results of operations and financial
condition.
YEAR 2000
The Company has assessed the potential impact the Year 2000 problem will have
on its financial condition and operations, and has determined that there will
be no material impact thereon.
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF
1995
Statements in this document which relate to other than strictly historical
facts, including statements about the Company's plans and strategies, as well
as management's expectations about new and existing products, technologies and
opportunities, market growth, demand for and acceptance of new and existing
products (including the PAPNET Testing System and the OxyNet oxygen
concentration device), are forward looking statements. The words "believe,"
"expect," "anticipate," "estimate," "project," and similar expressions identify
forward-looking statements that speak only as of the date hereof. Investors
are cautioned that such statements involve risks and uncertainties that could
cause actual results to differ materially from historical or anticipated
results due to many factors including, but are not limited to, the Company's
current reliance on a single product marketed under license from NSI, the
corresponding dependence on NSI's patents and proprietary technology,
government regulation, continuing losses from operations and negative cash
flow, limited marketing and sales history, the impact of third
15
<PAGE> 16
party reimbursement decisions, the challenges of research and development of
new products, and other risks detailed in this report and other Securities and
Exchange Commission filings. The Company undertakes no obligation to publicly
update or revise any forward-looking statements.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK
Not Applicable.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
The response to this Item is submitted in a separate section of this Report.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE.
None.
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT.
BOARD OF DIRECTORS
David J. Richards, age 47, a founder of the Company, has served as
President and director of the Company since its inception. From 1981 until
commencing employment with the Company, Mr. Richards was a practicing attorney
and, from 1983, a partner, in the law firm of Crabbe, Brown, Jones, Potts &
Schmidt in Columbus, Ohio. From 1985 through 1994, Mr. Richards was engaged in
real estate development as President of Sunset Development, a multi-family
housing developer. Mr. Richards has an accounting degree from Wright State
University, and earned his Juris Doctor degree from The Ohio State University
College of Law in 1977.
S. Trevor Ferger, age 45, is the Chief Operating Officer of the Company,
and has served as a director since December, 1996. He is also President of
Ferger & Associates, a sales consulting firm. He started his career with
Procter & Gamble and had sales management responsibilities in Atlanta, Georgia;
Jacksonville, Florida; and Raleigh, North Carolina. After obtaining an MBA
Degree from Xavier University in Cincinnati, he started a sales and marketing
firm specializing in the sales and marketing of consumer goods to grocery
stores, which merged into Acosta Sales of Jacksonville, Florida in October
1996.
Cecil J. Petitti, age 45, has been co-owner of Chaney & Petitti Insurance
Agency located in Dublin, Ohio since 1984. Chaney & Petitti specialize in
multiple insurance products, including medical insurance. Prior to merging
with the Chaney Group, Mr. Petitti was associated with the Burke, Kendall &
Petitti Insurance Agency. Mr. Petitti is also President of NetWalk, Inc., a
Columbus-based Internet service provider, and CallTech Communications, Inc., a
company providing telemarketing services and customer care outsourcing. Mr.
Petitti earned a Bachelor of Arts degree in Education from The Ohio State
University. Mr. Petitti has been a director of the Company since June, 1994.
Michael S. Blue, M.D., age 44, has been a practicing physician since 1980.
Dr. Blue graduated from Miami University of Ohio in 1976 with a Bachelor of
Science in Zoology and graduated from The Ohio State University with a Doctor
of Medicine in 1979. Dr. Blue has been President of Phoenix Group
International, Ltd. and North American International Trade Group, Inc. since
1994 and 1992, respectively. He has also been Secretary/Treasurer and member
of the Board of Directors of Columbus Oilfield Exploration, Inc. since 1987.
Dr. Blue has been a director of the Company since December 1996.
Robert J. Massey, age 53, has served on the Board of Directors of the
Company since January, 1997. He is currently President of RJM & Associates, a
Columbus, Ohio based consulting firm, and a principal in CallTech
Communications, Inc., a company providing telemarketing services and customer
care outsourcing. Prior to his affiliation with these businesses, he was
President, Chief Executive Officer and a director of CompuServe Corporation,
culminating an over twenty year career with the firm as an executive with
responsibilities in sales,
16
<PAGE> 17
marketing and general management. Mr. Massey is a director of Hublink, Inc., a
Columbus-based software company, and serves on various advisory boards,
including that of Gray Peak Technologies, a New York City-based network
technologies consulting firm. He is a graduate of Holy Cross College,
Worchester, Massachusetts and received an MBA in Finance from Syracuse
University.
Susan M. O'Toole, age 49, has served on the Board of Directors since May,
1998. Ms. O'Toole is an independent consultant operating fashion design services
in Dublin, Ohio. From 1996 through 1998, Ms. O'Toole served as Executive Vice
President and advisory board member of Retail Apparel Group, Inc., a
privately-held retail apparel company based in Cleveland, Ohio. From 1987 to
1996, Ms. O'Toole was a senior operating executive with The Limited, Inc. in
Columbus, Ohio, serving as President of its Limited Too division from 1993-1996.
Prior to joining The Limited, Ms. O'Toole was Executive Vice President of
Seifert's, a specialty retailer, from 1971 to 1987.
James F. Zid , age 65, has served on the Board of Directors of the Company
since February, 1997. Mr. Zid retired as the managing partner of the Columbus
office of Ernst & Young LLP in 1993. Mr. Zid currently serves on the Board of
Directors of Neoprobe Corporation and Central Benefits Insurance Company.
MEETINGS AND COMMITTEES OF THE BOARD OF DIRECTORS
The Board of Directors of the Company had a total of 5 meetings during the
year ended December 31, 1998. During 1998 each of the directors attended 75%
or more of the total number of (i) meetings of the Board, and (ii) meetings of
committees of the Board on which such director served. Directors who are not
employees of the Company received no cash compensation or expense reimbursement
for their services. In 1998 and prior years, non-employee directors received
stock options as compensation for their services.
The Board of Directors has an Audit Committee consisting of Messrs.
Richards, Blue and Ferger and a Compensation Committee consisting of Messrs.
Blue, Petitti, and Massey. The Audit Committee is charged with reviewing the
Company's annual audit and meeting with the Company's independent accountants
to review the Company's internal controls and financial management practices.
The Compensation Committee has the authority and responsibility to determine
and administer the Company's officer compensation policies and to establish the
salaries for executive officers, the formula for bonus awards to executive
officers, and the grant of stock options to executive officers and other key
employees under the Company's 1995 Amended and Restated Stock Option Plan (the
"Option Plan").
EXECUTIVE OFFICERS
In addition to David J. Richards and S. Trevor Ferger, the following
person is an executive officer of the Company:
Kenneth B. Leachman, age 45, was elected as Vice President of Finance in
October, 1996. Mr. Leachman has held various financial management positions
with several technology based companies, including Corporate Controller for
Goal Systems International from 1989 to 1991 and as Chief Financial Officer of
Sarcom, Inc. from 1992 to 1994. Mr. Leachman earned a Bachelor of Science
degree in accounting from The Ohio State University in 1975 and his CPA
certificate from the State of Ohio in 1977.
Officers are elected annually by the Board of Directors and serve at its
discretion. There are no family relationships among directors and executive
officers of the Company.
SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Section 16(a) of the Securities Exchange Act of 1934 requires the
Company's officers, directors, and persons who are beneficial owners of more
than ten percent of the Company's Common Stock to file reports of ownership and
changes in ownership with the Securities and Exchange Commission. Reporting
persons are required by Securities and Exchange Commission regulations to
furnish the Company with copies of all Section 16(a) forms filed by them.
Based on its review of the copies of Section 16(a) forms received by it and
written representations from reporting persons, the Company believes that all
filing requirements applicable to its reporting persons were complied with
during 1998, except that the initial report of beneficial ownership on Form 3
of Susan M. O'Toole, required to be filed within 10 days after her election to
the Board of Directors in May 1998, was not filed until February, 1999. As
filed, the Form 3 discloses that Ms. O'Toole owned no common shares at any time
up to the date of filing of the report.
17
<PAGE> 18
ITEM 11. EXECUTIVE COMPENSATION.
COMPENSATION OF NAMED EXECUTIVE OFFICERS
The following table sets forth certain information regarding compensation
paid during each of the Company's last three fiscal years to the Company's
Chief Executive Officer, and the only other executive officer whose combined
salary and bonus exceeded $100,000 for the fiscal year ended December 31, 1998
(collectively, the "Named Executive Officers").
SUMMARY COMPENSATION TABLE
<TABLE>
<CAPTION>
LONG-TERM
ANNUAL COMPENSATION COMPENSATION
--------------------- -------------
AWARDS
----------
SECURITIES
UNDERLYING ALL OTHER
SALARY BONUS OPTIONS COMPENSATION
NAME AND PRINCIPAL POSITION YEAR ($) ($) (#) ($)(1)
- --------------------------- ---- --------- ------- ---------- -------------
<S> <C> <C> <C> <C> <C>
David J. Richards,
President and Chief
Executive Officer 1998 $112,558 0 99,000 $15,435
1997 $200,000 $ 50,000 150,000(3) $16,259
1996 $125,000 $100,000(2) 0 $ 9,338
Kenneth B. Leachman, Vice
President-Finance and
Chief Fianancial Officer 1998 $ 85,422 0 33,000 $ 6,207
1997 $100,000 0 50,000(3) $ 8,004
</TABLE>
(1) Includes matching contribution to the Company's 401(k) Plan, car
allowance and excess group term insurance.
(2) Consists of a $50,000 cash bonus for 1995, which was paid in 1996 and
$50,000 represented by the forgiveness of indebtedness to the Company,
which was approved by the Board of Directors in 1995 and conditioned on
completion of the merger described below under "Certain Relationships and
Related Party Transactions."
(3) Options granted in 1997 were cancelled with the options granted in 1998
serving as replacement options.
18
<PAGE> 19
OPTION GRANTS IN LATEST FISCAL YEAR
The following table provides certain information regarding stock options
granted during 1998 to each of the Named Executive Officers.
<TABLE>
<CAPTION>
INDIVIDUAL GRANTS
- ----------------------------------------------------------------------------------------------------------------
(a) (b) (c) (d) (e) (f) (g)
% OF TOTAL
OPTIONS
GRANTED TO MARKET
OPTIONS EMPLOYEES EXERCISE PRICE ON GRANT DATE
GRANTED IN FISCAL PRICE GRANT DATE EXPIRATION PRESENT VALUE
NAME (#) YEAR ($/SH) ($/SH) DATE ($)(1)
- ----------------------- ---------- ---------- -------- ---------- ---------- -------------
<S> <C> <C> <C> <C> <C> <C>
David J. Richards(2) 99,000(2) 17.24 $ .50 $ .50 4/1/07 $22,770
156,248(3) 27.20 $1.12 $1.12 12/31/00 $50,000
Kenneth B. Leachman(3) 33,000(2) 5.75 $ .50 $ .50 12/10/06 $ 7,590
12,496(3) 2.18 $1.12 $1.12 12/31/00 $ 3,998
</TABLE>
(1) The amounts under the column labeled "Grant
Date Present Value ($)" are included by the Company pursuant
to certain rules promulgated by the Securities and Exchange
Commission and are not intended to forecast future
appreciation, if any, in the price of the Company's Common
Shares. Such amounts are calculated by application of the
Black-Scholes option pricing fomula, which yields a valuation
based upon certain assumptions, including that the price
volatility of the stock will follow historic patterns and
that the option holders hold the options granted for their
full term. The actual realizable value of the options will
vary in accordance with the market price of the Company's
Common Shares and may differ substantially from the value
produced by application of the formula. As of the date of
this report, the exercise prices of all of the options
referenced in this table substantially exceed the current
market value of the Company's Common Shares, and the market
price of the Company's Common Shares would have to increase
substantially over the term of these options for them ever to
have any realizable value.
(2) Options were granted as part of repricing which
occurred in 1998. Named Executive Officers surrendered
options granted in 1997 and received 66% of total as part of
repricing. The compensation committee considered overall
business conditions and the cash compensation paid to the
Named Executive Officers when approving the repricing.
(3) Options were granted effective May 1, 1998 in
conjunction with a salary reduction by Named Executive
Officers.
19
<PAGE> 20
AGGREGATED OPTION EXERCISES AND FISCAL YEAR-END OPTION VALUE TABLE
The following table provides certain information regarding the number and
value of stock options held by the Named Executive Officers at December 31,
1998.
<TABLE>
<CAPTION>
NUMBER OF SECURITIES
UNDERLYING UNEXERCISED VALUE OF UNEXERCISED
OPTIONS AT FISCAL IN-THE-MONEY OPTIONS AT
YEAR-END (#) FISCAL YEAR-END ($)(1)
SHARES ------------------------ ------------------------
ACQUIRED ON
EXERCISE VALUE
NAME (#) REALIZED ($) EXERCISABLE UNEXERCISABLE EXERCISABLE UNEXERCISABLE
- ------------------ ----------- ------------ ----------- ------------- ----------- -------------
<S> <C> <C> <C> <C> <C> <C>
David J. Richards -- -- 476,268 -- -- --
Kenneth B. Leachman -- -- 28,996 -- -- --
</TABLE>
(1) Represents the total gain which would be realized if all in-the-money
options held at year end were exercised, determined by multiplying the
number of shares underlying the options by the difference between the per
share option exercise price and the per share fair market value at year
end ($.2188 on December 31, 1998). An option is in-the-money if the fair
market value of the underlying shares exceeds the exercise price of the
option.
TEN-YEAR OPTION REPRICINGS
In July, 1998, the Board of Directors approved the issuance to certain
directors, officers and employees of options to purchase 230,140 common shares
at a price of $.50 per share, in exchange for the surrender of options to
purchase 321,000 common shares at exercise prices ranging from $4.95 to $12.00
per share. Included in these options were options for 99,000 shares granted to
Mr. Richards (in exchange for the surrender of options for 150,000 shares
exercisable at prices ranging from $6.94 to $12.00 per share), and options for
33,000 shares granted to Mr. Leachman (in exchange for the surrender of options
for 50,000 shares exercisable at $5.95 per share). The Board took this action
to restore some potential compensatory value to employees and directors of
equity incentives that had been rendered essentially valueless by substantial
declines in the market price of the Company's common shares, due to factors
beyond their control. The following table provides information on the
repricing with respect to certain stock options held by the Named Executive
Officers:
<TABLE>
<CAPTION>
Name Date Number of Number of Market Price Exercise Price New Length of Original
Options Canceled of Stock of Canceled Exercise Option term
Canceled Options at time of Options at Time Price Remaining at Date
Replaced Replacement of Replacement of Replacement
<S> <C> <C> <C> <C> <C> <C> <C>
David J. Richards 7/21/98 50,000 33,000 $ 0.50 $ 6.94 $0.50 8 years 9 months
David J. Richards 7/21/98 50,000 33,000 $ 0.50 $ 10.00 $0.50 9 years 9 months
David J. Richards 7/21/98 50,000 33,000 $ 0.50 $ 12.00 $0.50 10 years 9 months
Kenneth B. Leachman 7/21/98 50,000 33,000 $ 0.50 $ 5.95 $0.50 8 years 5 months
</TABLE>
COMPENSATION OF DIRECTORS
Directors who are not employees of the Company receive no cash
compensation or expense reimbursement, but receive stock options as
compensation for their services. The exercise price for options granted in
1996 and prior years ranges from $3.25 to $11.00 per share. During 1998,
Mesrs. Ferger, Petitti, Blue and Massey surrendered a total of 85,000 options
exercisable at prices from $6.16 to $7.54 per share in exchange for a total of
72,000 options (18,000 per director) exercisable at $.50 per share. At the
same time, Mr. Zid and Ms. O'Toole were granted 18,000 options exercisable at
$.50 per share. All options vest in equal annual amounts over a three year
period of service. In addition, Messrs. Ferger and Petitti each exchanged
2,000 fully vested options having an exercise price of $8.40 per share, for
1,320 options exercisable at $.50 per share. All director options terminate 10
years from the date of grant.
20
<PAGE> 21
EMPLOYMENT CONTRACTS WITH NAMED EXECUTIVE OFFICERS
Effective April 1, 1997, the Company entered into an employment agreement
with Mr. Richards, its President and Chief Executive Officer. The Agreement
was for a term of three years, and provides for annual base salary of $225,000
during the term. In addition to the base salary, the agreement provides that
Mr. Richards will receive an annual incentive bonus of up to 100% of his base
salary, to be determined according to performance criteria established by the
Board or its Compensation Committee, as well as an automobile allowance,
Company-provided term insurance in a minimum face amount of $1,000,000, and
other benefits. In July, 1998, in the conjunction with certain measures taken
by the Board of Directors to conserve cash, Mr. Richards agreed to the
indefinite suspension of cash salary and bonus under the agreement.
The agreement also provides for the grant, pursuant to the Option Plan, of
options to purchase 150,000 common shares, vesting at the rate of 50,000 shares
per employment year during the term, with exercise prices ranging from $6.94
per share to $12.00 per share. These options have since been surrendered in
exchange for new options. See "Option Repricing." The agreement provides
that, in the event that Mr. Richards' employment is terminated other than for
good cause (as defined in the agreement), or is constructively terminated, the
Company will continue his base salary and health insurance coverage for a
period of 18 months after termination and pay any earned but unpaid incentive
bonus, and that the options granted pursuant to the agreement will become
immediately exercisable. For purposes of the agreement, a constructive
termination is defined as removal of Mr. Richards as President, Chief Executive
Officer or a Director of the Company, or a substantial change in his duties or
reporting responsibility to the Board. In the event of a "Change of Control"
(as defined in the Agreement), Mr. Richards may voluntarily terminate his
employment at any time within one year thereafter, if (i) he determines in good
faith that as a result of the Change of Control he can no longer adequately
exercise the authority, powers, functions or duties of a chief executive
officer, or can no longer perform such duties by reason of a substantial
diminution in his responsibilities, status, perquisites or position, or (ii)
the Company materially breaches or fails to assume any material obligation
under the agreement. In the event of such termination, the Company will pay
Mr. Richards 18 months of base salary in a lump sum, reimbursement of any
previously unreimbursed business expenses, and an amount equal to the greater
of (A) the full incentive bonus for which he could receive under any bonus
criteria established by the Board of Directors for the employment year in which
termination occurs (regardless of whether such criteria are actually
satisfied), or (B) the incentive bonus actually paid to him during the previous
employment year. In addition, the Company must continue his health insurance
benefits for a period of 18 months, and the options granted pursuant to the
agreement will become immediately exercisable. The foregoing obligations of
the Company also apply in the event that Mr. Richards' employment is terminated
by the Company other than for cause within one (1) year following a Change of
Control.
In the event of Mr. Richards' death during the employment term, in
addition to the payment of salary and bonus earned to the date of death, and
the immediate exercisability of stock options, the agreement provides that the
Company will purchase from his estate of up to $2 million in market value of
common shares of the Company owned by Mr. Richards on the date of death. The
agreement requires the Company to purchase and pay the premiums on a policy of
key man life insurance sufficient to fund such obligation. Finally, the
agreement imposes confidentiality and noncompetition obligations on Mr.
Richards, and requires that he assign to the Company any intellectual property
(inventions, trade secrets, works of authorship, and the like) created by him
during his employment which is useful in the Company's business.
REPORT ON 1998 EXECUTIVE COMPENSATION
The Company's compensation policies were originally designed to attract,
retain and motivate the executive talent required to achieve the Company's
business objectives and to increase shareholder value. Prior to 1997, the
executive compensation policies and decisions were made by the entire Board of
Directors. Thereafter, executive compensation and stock option awards have
been determined by a Compensation Committee (the "Committee"), which currently
consists of Messrs. Blue, Petitti and Massey. The Committee plans to annually
review the competitiveness of the Company's executive compensation programs.
Because of the continuing decline in revenue from sales of the PAPNET
product, during 1998 management implemented a number of expense reductions,
including the reduction of general and administrative headcount and substantial
reductions of the cash compensation paid to certain officers. Beginning in the
third quarter of 1998, cash compensation of certain officers was discontinued
until such time as the Company's Board of Directors is satisfied that the
Company has the ability to fund operations from either internal or external
sources. During 1998, no officer received any cash bonus or increase in
compensation. To partially offset the impact of salary reductions, new
21
<PAGE> 22
options were awarded to officers and certain outstanding options were repriced,
as described above.
Compensation Committee: Cecil J. Petitti, Michael S. Blue, M.D., Robert J.
Massey.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.
SECURITY OWNERSHIP BY MANAGEMENT
The following table sets forth information regarding beneficial ownership
of the Company's Common Shares by each director, the Company's executive
officers named in the Summary Compensation Table, and the directors and
executive officers of the Company as a group as of March 18, 1999:
<TABLE>
<CAPTION>
SHARES BENEFICIALLY OWNED (1)
-----------------------------
NAME OF BENEFICIAL OWNER NUMBER PERCENT
- ---------------------------------------- ---------- ------------
<S> <C> <C>
David J. Richards(2) 1,516,150 12.26
S. Trevor Ferger(3) 422,145 3.41
Cecil J. Petitti(4) 165,296 1.34
Michael S. Blue(5) 298,717 2.42
Robert J. Massey(6) 60,922 *
James F. Zid(7) 17,800 *
Kenneth B. Leachman(8) 50,996 *
All directors and executive officers as a group
(7 persons) 2,532,026 20.48
</TABLE>
- ----------------
* Represents beneficial ownership of less than 1% of the Company's
outstanding Common Shares.
(1) Beneficial ownership is determined in accordance with the rules of the
Securities and Exchange Commission which generally attribute beneficial
ownership of securities to persons who possess sole or shared voting power
and/or investment power or as to which the person has the right to acquire
the beneficial ownership within 60 days of March 31, 1999. Unless
otherwise indicated, voting power and investment power are exercised
solely by the person named above or shared with members of his household.
(2) Includes 509,268 shares which may be purchased under stock options
exercisable within 60 days of March 31, 1999.
(3) Includes 138,320 shares which may be purchased under stock options
exercisable within 60 days of March 31, 1999.
(4) Includes 15,320 shares which may be purchased under stock options
exercisable within 60 days of March 31, 1999.
(5) Includes 12,000 shares which may be purchased under stock options
exercisable within 60 days of March 31, 1999.
(6) Includes 12,000 shares which may be purchased under stock options
exercisable within 60 days of March 31, 1999.
(7) Includes 12,000 shares which may be purchased under stock options
exercisable within 60 days of March 31, 1999.
(8) Includes 28,996 shares which may be purchased under stock options
exercisable within 60 days of March 31, 1999.
SECURITY OWNERSHIP BY PRINCIPAL SHAREHOLDERS
The following table sets forth information as of March 18, 1999 relating
to the beneficial ownership of Common Shares by each person known by the
Company to own beneficially more than 5% of the outstanding Common Shares.
22
<PAGE> 23
<TABLE>
<CAPTION>
SHARES BENEFICIALLY OWNED (1)
-----------------------------
NAME OF BENEFICIAL OWNER NUMBER PERCENT
- ------------------------ ---------- ----------
<S> <C> <C>
David J. Richards(2) 1,516,150 12.26
</TABLE>
- -------------------
(1) Beneficial ownership is determined in accordance with the rules of the
Securities and Exchange Commission which generally attribute beneficial
ownership of securities to persons who possess sole or shared voting power
and/or investment power or as to which the person has the right to acquire
the beneficial ownership within 60 days of March 31, 1999. Unless
otherwise indicated, voting power and investment power are exercised
solely by the person named above or shared with members of his household.
(2) Includes 509,268 shares which may be purchased under stock options
exercisable within 60 days of March 31, 1999. Mr. Richards' address is
6189 Memorial Drive, Dublin, Ohio 43017.
Holders of the Company's outstanding Series A, 6% Convertible Preferred
Stock have the right to convert the preferred stock and any dividends accrued
into NetMed common shares at any time. The preferred stock is entitled to
cumulative annual dividends at the rate of 6% of stated value payable in common
shares at the time of each conversion, and is convertible into shares of NetMed
common stock based on the "Conversion Price" at the time of conversion. The
Conversion Price is an amount equal to 75% of the average closing bid price of
NetMed common shares on the American Stock Exchange for the previous three
business days ending on the day before the conversion date. The Conversion
Price is subject to equitable adjustment upon the occurrence of certain events,
such as stock splits, stock dividends, reclassifications or combinations. As
of March 18, 1999, there were 94,382 shares of preferred stock outstanding, and
based upon the average closing bid price of NetMed's common shares on the three
previous business days, were convertible on that date into 15,121,254 common
shares. Under the terms of the preferred stock, however, the holders are
precluded from effecting any conversion if the conversion would result in them
owning more than 4.99% of NetMed's outstanding common stock. Consequently,
the number of shares of common stock issuable on conversion of the preferred
stock has been excluded from the foregoing tables. The holders of the
preferred stock are CPR (USA), Inc., LibertyView Fund, LLC, and LibertyView
Plus Fund, affiliates of Banque CPR, a French broker-dealer, with offices
located at 101 Hudson Street, Suite 3700, Jersey City, New Jersey 07302.
The following Performance Graph shall not be deemed incorporated by reference
by any general statement incorporating by reference this Report into any of the
Company's filings under the Securities Act of 1933, as amended, or the
Securities Exchange Act of 1934, as amended, except to the extent that the
Company specifically incorporates this information by reference, and shall not
otherwise be deemed filed under such Acts.
PERFORMANCE GRAPH
COMPARISON OF 55 MONTH CUMULATIVE TOTAL RETURN* AMONG
THE COMPANY, THE AMEX MARKET VALUE INDEX, THE S&P HEALTH CARE
(MEDICAL PRODUCTS & SUPPLIES) INDEX AND A CERVICAL CYTOLOGY PEER GROUP INDEX
The following Performance Graph compares the performance of the Company
with that of the AMEX Market Value Index, the S&P Health Care (Medical Products
& Supplies) Index, and an index composed of a peer group of cervical cytology
companies (the "Peer Group"). The Peer Group consists of Accumed,
International Inc. (ACMIC), Autocyte, Inc. (ACYT), Cytyc Corp. (CYTC), Neopath,
Inc. (NPTH) and Neuromedical Systems, Inc. (NSIX). The comparison of the
cumulative total return to shareholders for each of the periods assumes that
$100 was invested on May 12, 1994 in the Company's Common Shares, and in the
AMEX Market Value Index, the S&P Health Care (Medical Products & Supplies)
Index and the Peer Group, and that all dividends were reinvested.
23
<PAGE> 24
<TABLE>
COMPARISON OF 55 MONTH CUMULATIVE TOTAL RETURN*
AMONG NETMED, INC, THE AMEX MARKET VALUE INDEX,
THE S & P HEALTH CARE (MEDICAL PRODUCTS & SUPPLIES) INDEX
AND A PEER GROUP
<CAPTION>
CUMULATIVE TOTAL RETURN
------------------------------------------------------------
5/12/94 12/94 12/95 12/96 12/97 12/98
<S> <C> <C> <C> <C> <C> <C>
NETMED, INC. 100 93 357 227 64 6
PEER GROUP 100 50 100 73 43 31
AMEX MARKET VALUE 100 99 125 133 161 164
S&P HEALTH CARE (MEDICAL
PRODUCTS & SUPPLIES) 100 125 211 243 302 436
</TABLE>
* $100 INVESTED ON 5/12/94 IN STOCK OR ON 4/30/94 IN INDEX - INCLUDING
REINVESTMENT OF DIVIDENDS. FISCAL YEAR ENDING DECEMBER 31.
24
<PAGE> 25
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.
In September 1997, the Company entered into a net lease with Muirfield
Square, Ltd. for 4,900 square feet of office space in which the Company's
principal offices are located. The lease term is for 5 years at an annual rent
of $53,900 for the first year, escalating annually at the rate of 3% over the
term, and renewable for an additional 5-year term at an annual net rental of
$60,660. Messrs. Richards, Ferger, and Massey own a majority of the membership
interests in Muirfield Square, Ltd. The Company believes that the lease is on
terms at least as favorable to the Company as available for office space of a
similar size and quality in the locality.
In January, 1998, the Company entered into a consulting arrangement with
Ferger & Associates ("Consultant"), a company controlled by Mr. Ferger, under
which the Consultant will assist the Company in its marketing and sales
activities, including management of the sales force. Under this arrangement,
the Company has agreed to pay the Consultant $100,000 annually, in monthly
installments, plus reimbursement of reasonable expenses. The term of the
arrangement was originally for three years, but was cancelled upon Mr. Ferger
becoming employed by the Company effective May 1, 1998.
PART IV
ITEM 14. EXHIBITS AND REPORTS ON FORM 8-K.
(a) The following documents are filed as part of this Annual Report on
Form 10-K:
(1) The following financial statements are included in this report under
Item 8:
Consolidated Balance Sheet as of December 31, 1998 and 1997.
Consolidated Statements of Operations for the three
years ended December 31, 1998.
Consolidated Statements of Stockholders' Equity for the
three years ended December 31, 1998.
Consolidated Statements of Cash Flows for the three
years ended December 31, 1998.
Notes to the Consolidated Financial Statements.
Independent Auditors' Report.
(2) Financial Statement Schedules: Schedules not listed above have
been omitted because the information required to be set forth
therein is not applicable or is shown in the accompanying
Consolidated Financial Statements.
(3) Exhibits:
EXHIBIT
NUMBER DESCRIPTION
------- -----------
3.1 Amended and Restated Articles of Incorporation of the
Registrant. (Previously filed as Appendix A to the Registration
Statement on Form S-4, Registration No. 333-8199, and incorporated
herein by reference.)
3.2 Amended and Restated Regulations of the Registrant. (Previously
filed as Appendix A to the Registration Statement on Form S-4,
Registration No. 333-8199, and incorporated herein by reference.)
25
<PAGE> 26
3.3 Form of Specimen Stock Certificate. (Previously filed as
Exhibit 3(e) to the Registration Statement on Form S-4, Registration
No. 333-8199, and incorporated herein by reference.)
4.1 Articles FOURTH, SIXTH, SEVENTH, EIGHTH, TENTH, and ELEVENTH,
of the Registrant's Amended and Restated Articles of Incorporation
and Articles I, V and VII of the Registrant's Amended and Restated
Regulations. (Previously filed as Exhibit 4(b) to the Registration
Statement on Form S-4, Registration No. 333-8199, and incorporated
herein by reference.)
10.1 Amended and Restated 1995 Stock Option Plan of the Registrant.
(Previously filed as Exhibit 10(i) to the Registration Statement on
Form S-4, Registration No. 333-8199, and incorporated herein by
reference.)
10.2 Net Lease between Muirfield Square, Ltd. as Lessor and Registrant
as Lessee, dated September 15, 1997. (Previously filed as Exhibit 10.9
to the Registration Statement on Form S-1, Registration No. 333-35663,
and incorporated herein by reference.)
10.3 Investment Agreement among the Registrant, CeramPhysics, Inc. and
Ceram Oxygen Technologies, Inc., dated February 28, 1997. (Previously
filed as Exhibit 10(j) to Registrant's 1996 Annual Report on Form
10-K, Commission file no. 1-12529, and incorporated herein by
reference.)
10.4 Revolving Loan-Grid Note, between the Registrant as the lender
and Ceram Oxygen Technologies, Inc. as maker, dated February 28, 1997,
as amended December 16, 1997. (Previously filed as Exhibit 10.7 to
Registrant's 1997 Annual Report on Form 10-K, Commission file no.
1-12529, and incorporated herein by reference.)
10.5 Employment Agreement between the Registrant and David J.
Richards, dated as of April 1, 1997. (Previously filed as Exhibit
10(a) to Registrant's Quarterly Report on Form 10-Q for the quarter
ending June 30, 1997, and incorporated herein by reference.)
21 * Subsidiaries of the Registrant
23 * Consent of Ernst & Young, LLP.
24 * Powers of Attorney.
27 * Financial Data Schedule.
99.1 Convertible Debenture Exchange Agreement, dated October 27, 1998,
among the Registrant, CPR (USA) Inc., LibertyView Fund, LLC, and
LibertyView Plus Fund. (Previously filed as Exhibit 99.1 to
Post-Effective Amendment No. 2 to Form S-1 on Form S-3, Registration
No. 333-35663, and incorporated herein by reference.)
99.2 Registration Rights Agreement, dated October 27, 1998, among the
Registrant, CPR (USA) Inc., LibertyView Fund, LLC, and LibertyView
Plus Fund. (Previously filed as Exhibit 99.2 to Post-Effective
Amendment No. 2 to Form S-1 on Form S-3, Registration No. 333-35663,
and incorporated herein by reference.)
99.3 Amended and Restated Agreement, dated November 23, 1998, between
Neuromedical Systems, Inc. and the Registrant. (Previously filed as
Exhibit 99.3 to Post-Effective Amendment No. 2 to Form S-1 on Form
S-3, Registration No. 333-35663, and incorporated herein by
reference.)
99.4 Registration Rights Agreement, dated August 12, 1997, between the
Registrant and CPR (USA), Inc. (Previously filed as Exhibit 99.4 to
the Registration Statement on Form S-1, Registration No. 333-35663,
and incorporated herein by reference.)
26
<PAGE> 27
* Filed with this Report.
(b) Reports on Form 8-K
The Company filed the following Current Report on Form 8-K in the
fourth quarter of 1998:
Current Report on Form 8-K, dated October 30, 1998, filed with the
Securities and Exchange Commission on November 5, 1998 (Item 5).
(c) Exhibits
The exhibits to this report begin on page 29.
27
<PAGE> 28
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
NetMed, Inc.
Date: March 29,1999 By: /s/ David J. Richards
-----------------------------------
David J. Richards, President
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
Registrant and in the capacities indicated on the 29th day of March, 1999.
Signature Title
/s/ David J. Richards President, Chief Executive Officer and Director
- ------------------------
David J. Richards
*S. Trevor Ferger Chief Operating Officer and Director
- ------------------------
S. Trevor Ferger
*Kenneth B. Leachman Vice President - Finance
- ------------------------ (Principal Accounting Officer)
Kenneth B. Leachman
*Cecil J. Petitti Director
- ------------------------
Cecil J. Petitti
*James F. Zid Director
- ------------------------
James F. Zid
*Michael S. Blue Director
- ------------------------
Michael S. Blue
*Robert J. Massey Director
- ------------------------
Robert J. Massey
*Susan M. O'Toole Director
- ------------------------
Susan M. O'Toole
*By: /s/ David J. Richards
-------------------------------------
David J. Richards, Attorney in fact
28
<PAGE> 29
Annual Report on Form 10-K
Item 8, Item 14(a)(1) and (2), (c) and (d)
Financial Statements and Supplementary Data
List of Financial Statements and Financial Statement Schedules
Certain Exhibits
Financial Statement Schedules
Year ended December 31, 1998
NetMed, Inc.
Dublin, Ohio
29
<PAGE> 30
NetMed, Inc.
and Subsidiary
Audited Consolidated Financial Statements
Years ended December 31, 1998, 1997 and 1996
CONTENTS
<TABLE>
<S> <C>
Report of Independent Auditors................... 1
Audited Consolidated Financial Statements
Consolidated Balance Sheets...................... 2
Consolidated Statements of Operations............ 3
Consolidated Statements of Stockholders' Equity.. 4
Consolidated Statements of Cash Flows............ 5
Notes to Consolidated Financial Statements....... 6
</TABLE>
F-1
<PAGE> 31
Report of Independent Auditors
The Board of Directors and Stockholders
NetMed, Inc.
We have audited the accompanying consolidated balance sheets of NetMed, Inc.
and subsidiary (the Company) as of December 31, 1998 and 1997, and the related
consolidated statements of operations, stockholders' equity and cash flows for
each of the three years in the period ended December 31, 1998. These financial
statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of
material misstatement. An audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements. An audit
also includes assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a reasonable basis
for our opinion.
In our opinion, the consolidated financial statements referred to above present
fairly, in all material respects, the consolidated financial position of the
Company at December 31, 1998 and 1997, and the consolidated results of its
operations and its cash flows for each of the three years in the period ended
December 31, 1998, in conformity with generally accepted accounting principles.
As discussed in Note 14 to the consolidated financial statements, the Company's
recurring losses, decreasing revenues, and net capital deficiency raise
substantial doubt about its ability to continue as a going concern.
Management's plans as to these matters are described in Note 14. The
consolidated financial statements do not include any adjustments that might
result from the outcome of this uncertainty.
ERNST & YOUNG, LLP
Columbus, Ohio
January 29, 1999
(except as to Note 14 as to which
the date is March 26, 1999)
F-2
<PAGE> 32
NetMed, Inc.
Consolidated Balance Sheets
<TABLE>
<CAPTION>
DECEMBER 31
1998 1997
-------------- -------------
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents $ 513,712 $ 1,656,370
Accounts receivable 30,000 216,356
Prepaid assets 25,209 25,208
------------- ------------
Total current assets 568,921 1,897,934
Investment in NSI--available for sale 24,603 1,267,343
Notes receivable - NSI 6,757 21,443
Note receivable-COTI -- 278,499
Furniture and equipment (net of accumulated
depreciation of $65,302 -- 1998 and $46,095 -- 1997)
License (net of accumulated amortization 44,952 42,263
of $27,803--1998 and $0--1997) 565,323 --
Deferred taxes 260,100 260,100
Deposits and other assets 1,539 1,467
------------- ------------
Total assets $ 1,472,195 $ 3,769,049
============= ============
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities:
Accounts payable $ 51,282 $ 113,176
Accrued expenses 66,270 304,579
Other liabilities 143,489 69,102
------------- ------------
Total current liabilities 261,041 486,854
Deferred taxes 260,100 260,100
Convertible debentures 1,350,000 2,190,000
Minority interest 10,731 --
Preferred stock of subsidiary 491,000 --
Stockholders' equity:
Common stock, no par value, 20,000,000 shares
authorized, 11,987,604 and 11,080,783 issued and
outstanding at December 31, 1998 and 1997 6,184,968 5,417,151
Accumulated other comprehensive loss (361,261) (499,478)
Retained deficit (6,724,384) (4,085,578)
------------- ------------
Total stockholders' equity (deficit) (900,677) 832,095
------------- ------------
Total liabilities and stockholders' equity $ 1,472,195 $ 3,769,049
============= ============
</TABLE>
See accompanying notes.
F-3
<PAGE> 33
NetMed, Inc.
Consolidated Statements of Operations
<TABLE>
<CAPTION>
1998 1997 1996
------------- -------------- -------------
<S> <C> <C> <C>
Royalty revenue $ 399,848 $ 893,608 $ 102,813
Operating expenses:
Selling, general and administrative 1,569,136 3,053,255 1,329,797
Business development 399,610 293,952 85,476
Merger (Note 1) -- -- 364,852
------------ ------------- ------------
Operating expenses 1,968,746 3,347,207 1,780,125
------------ ------------- ------------
Operating loss (1,568,898) (2,453,599) (1,677,312)
Other income (expense):
Interest income 40,903 39,442 13,743
Interest expense (103,771) (72,464) (872)
(Loss) gain on sale of
available-for-sale securities (894,147) 794,819 664,057
Financing costs (118,750) (1,106,452) --
Equity loss in partnerships -- -- (13,451)
------------ ------------- ------------
Total other (expense) income (1,075,765) (344,655) 663,477
------------ ------------- ------------
Loss before income taxes and
minority interest (2,644,663) (2,798,254) (1,013,835)
Minority interest 5,857 -- --
Income tax expense (benefit) -- 486,022 (421,013)
------------ ------------- ------------
Net loss $(2,638,806) $(3,284,276) $ (592,822)
============ ============= ============
Net loss per share-
basic and diluted $ (.23) $ (.30) $ (.09)
============ ============= ============
</TABLE>
See accompanying notes.
F-4
<PAGE> 34
NetMed, Inc.
Consolidated Statements of Stockholders' Equity
<TABLE>
<CAPTION>
ACCUMULATED
OTHER RETAINED
COMPREHENSIVE EARNINGS
COMMON STOCK INCOME (LOSS) (DEFICIT) TOTAL
------------ ------------- --------- ----------
<S> <C> <C> <C> <C>
Balance, January 1, 1996 $2,562,542 $3,899,617 $(208,480) $6,253,679
Adjustment to unrealized gains net of tax - (1,710,691) - (1,710,691)
Net assets acquired via the Merger (Note 1) - 1,765,838 - 1,765,838
Net loss (592,822) (592,822)
-----------
Comprehensive income (537,675)
-----------
Net assets acquired via the Merger (Note 1) 905,463 905,463
Deferred compensation
stock options 410,000 - - 410,000
Stock options exercised 3,600 - (592,822) (592,822)
----------- -------------- ------------- -----------
Balance, December 31, 1996 3,881,605 3,954,764 (801,302) 7,035,067
Adjustment to unrealized gains net of tax (4,454,242) (4,454,242)
Net loss (3,284,276) (3,284,276)
-----------
Comprehensive income (7,738,518)
-----------
Deferred compensation
stock options 455,593 455,593
Warrants issued and discount on
convertible debentures 850,096 850,096
Stock issued 360,000 360,000
Stock received for note (Note 10) (130,143) (130,143)
----------- -------------- ------------- -----------
Balance, December 31, 1997 5,417,151 (499,478) (4,085,578) 832,095
Adjustment to unrealized loss 138,217 138,217
Net loss (2,638,806) (2,638,806)
-----------
Comprehensive income (2,500,589)
-----------
Deferred compensation
stock options 148,730 148,730
Options sold 61,664 61,664
Warrants issued and discount on
convertible debenture 129,750 129,750
Stock issued 427,673 427,673
----------- -------------- ------------- -----------
Balance, December 31, 1998 $6,184,968 $(361,261) $(6,724,384) $ (900,677)
=========== ============== ============= ===========
</TABLE>
See accompanying notes.
F-5
<PAGE> 35
NetMed, Inc.
Consolidated Statements of Cash Flows
<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31
1998 1997 1996
-------------- -------------- --------------
<S> <C> <C> <C>
OPERATING ACTIVITIES
Net loss $(2,638,806) $(3,284,276) $ (592,822)
Adjustments to reconcile net loss to net cash
used for operating activities:
Depreciation and amortization 47,010 13,696 7,776
Change in deferred taxes -- 484,062 (421,013)
Loss (gain) on available-for-sale securities 894,147 (794,819) (664,057)
Compensation on extended stock options 148,730 455,593 410,000
Warrants issued for consulting 38,374 -- --
Minority interest (5,857) -- --
Equity loss in partnership -- -- 13,451
Financing costs 118,750 850,096 --
Changes in operating assets and liabilities:
Accounts receivable 186,356 (170,987) (55,727)
Note receivable from stockholder -- -- 50,000
Prepaid assets (1) 3,186 (27,373)
Accounts payable (61,894) 15,551 47,694
Accrued expenses and other liabilities (129,908) 120,298 101,398
------------- ------------- -------------
Net cash used in operating activities (1,403,099) (2,307,600) (1,130,673)
------------- ------------- -------------
INVESTING ACTIVITIES
Sale of NSI stock -- 1,225,229 750,057
Acquisition of OxyNet (200,000) -- --
Net cash advances to Predecessor Companies in
contemplation of Merger -- -- (400,183)
Notes receivable - NSI 14,686 -- 29,637
Note receivable-COTI (84,931) (278,499) --
Purchase of furniture and equipment (21,896) (27,925) (18,494)
Other assets (82) -- (138)
------------- ------------- -------------
Net cash (used) provided by investing activities (292,223) 918,805 360,879
------------- ------------- -------------
FINANCING ACTIVITIES
Sale of options 61,664 -- --
Sale of preferred stock by subsidiary 491,000 -- --
Issuance of convertible debentures -- 3,000,000 --
Proceeds from margin account -- (96,909) 96,909
Issuance of common stock and warrants exercised -- -- 3,600
------------- ------------- -------------
Net cash provided by financing activities 552,664 2,903,091 100,509
------------- ------------- -------------
Net (decrease) increase in cash (1,142,658) 1,514,296 (669,285)
Cash and cash equivalents at beginning
of period 1,656,370 142,074 811,359
------------- ------------- -------------
Cash and cash equivalents at end of period $ 513,712 $ 1,656,370 $ 142,074
============= ============= =============
</TABLE>
See accompanying notes.
F-6
<PAGE> 36
NetMed, Inc.
Notes to Consolidated Financial Statements
1. ORGANIZATION AND BASIS OF PRESENTATION
NetMed, Inc. is engaged in the business of acquiring, developing and marketing
medical and health-related technologies. NetMed's revenues are currently
derived principally from the marketing of the PAPNET(R) Testing System, an
advanced computerized test that pinpoints and magnifies precancerous and
cancerous cells. NetMed is also investigating other medical technologies,
including the development of an oxygen concentrator device to be sold in the
home healthcare market. The consolidated financial statements include the
accounts of NetMed, Inc. and its majority owned subsidary (the "Company")
On December 5, 1996, the Company's shareholders approved an Agreement and Plan
of Merger (the "Merger Agreement") whereby Cytology Indiana, Inc., Indiana
Cytology Review Company, ER Group, Inc., CCWP Partners, Inc. (CCWP), and
Carolina Cytology, Inc. (the "Predecessor Companies") were merged with and into
the Company (the "Merger"). The Merger was effective on December 16, 1996 and
the Company issued, in the aggregate, 4,849,988 shares of its common stock,
without par value, in exchange for the issued and outstanding shares of the
Predecessor Companies. Under terms of the Merger Agreement, the Company
changed its name from Papnet of Ohio, Inc. to NetMed, Inc.
Prior to the Merger, Papnet of Ohio, Inc. and each of the Predecessor Companies
(except for CCWP) held long-term territorial license agreements ("License
Agreement") issued by Neuromedical Systems, Inc. (NSI). The License Agreements
provide the right to sell the "PAPNET(R) System" and the "PAPNET(R) Service",
as described below, in Ohio, Kentucky, Missouri, Georgia, North Carolina and
the Standard Metropolitan Area of Chicago. As a result of the Merger, and in
accordance with an agreement with NSI, the individual License Agreements held
by Papnet of Ohio, Inc. and the Predecessor Companies were exchanged for a
single License Agreement ("Amended License") that encompasses the same
territories covered by the individual License Agreements.
NSI, founded in 1988, is a healthcare technology company focused on diagnostic
screening applications to aid in the early detection of certain cancers. NSI's
first and to date only product, the PAPNET(R) System, was approved for
commercial use in the United States by the Food and Drug Administration (the
"FDA") on November 8, 1995. The PAPNET(R) Service permits laboratories to
submit Pap smear slides to one of NSI's central facilities for processing by
the PAPNET(R) System. NSI's objective is to establish the use of its PAPNET(R)
System as the new standard of care in cervical cancer screening.
F-7
<PAGE> 37
NetMed, Inc.
Notes to Consolidated Financial Statements
1. ORGANIZATION AND BASIS OF PRESENTATION (CONTINUED)
The Merger of NetMed and the Predecessor Companies occurred in connection with
the initial registration of the Company's common stock with the Securities and
Exchange Commission ("SEC") which resulted in the public trading of the
Company's common stock. The Merger was accounted for at historical cost based
on the guidance in SEC Staff Accounting Bulletins 48 and 97. The results of
operations of the Predecessor Companies have been combined with those of the
Company on a prospective basis commencing at the date of Merger. The following
displays summarized pro forma results of operations assuming the Merger
transaction occurred on January 1, 1996:
<TABLE>
<CAPTION>
PRO FORMA
YEAR ENDED
DECEMBER 31,
------------
1996
------------
<S> <C>
Royalty revenue $ 222,002
Operating loss (2,153,257)
Net (loss) income (1,032,865)
Net (loss) income per share (.10)
</TABLE>
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
USE OF ESTIMATES
The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements.
Estimates also affect the reported amounts of revenues and expenses during the
reporting period. Actual results may differ from these estimates.
CASH EQUIVALENTS
The Company considers all short-term deposits and highly liquid investments
purchased with an original maturity of three months or less to be cash
equivalents.
FURNITURE AND EQUIPMENT
Furniture and equipment consists of office furniture and computer equipment
recorded at cost which is being depreciated on an accelerated method over
estimated useful lives ranging from three to seven years.
F-8
<PAGE> 38
NetMed, Inc.
Notes to Consolidated Financial Statements
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
ROYALTY REVENUE
Pursuant to the License Agreement, the Company is entitled to receive 50% of
per slide revenues, less certain charges for equipment and transportation of
the slides generated by labs within the Company's territory. The Company earns
and accrues the net per slide revenue on a monthly basis. NSI is required to
pay this monthly amount by the end of the following month. This is the method
used by the Company to record royalty revenue in 1998, 1997 and 1996.
The License Agreement also provides a calculation for a minimum royalty to be
based upon the worldwide revenue of NSI. The minimum royalty is 3.5% of NSI's
worldwide revenue, and is to be paid within 90 days of year end if this
calculation yields a royalty greater than the royalty calculated from the
Company's territorial revenue.
INCOME TAXES
The Company accounts for income taxes using the liability method under
Statement of Financial Accounting Standards No. 109 "Accounting for Income
Taxes." Deferred items are determined based on differences between the
financial reporting and tax basis of assets and liabilities, and are measured
using the enacted rates and laws that will be in effect when the differences
are expected to reverse.
STOCK-BASED COMPENSATION
The Company accounts for stock compensation arrangements in accordance with APB
Opinion No. 25, "Accounting for Stock issued to Employees." The pro forma
information regarding income and earnings per share as required by Statement of
Financial Accounting Standards No.123, "Accounting for Stock-Based
Compensation" ("SFAS No. 123") is disclosed in "Note 6 - Stock Options and
Warrants."
RECLASSIFICATION
Certain amounts presented for 1997 and 1996 have been reclassified to conform
to the 1998 presentation.
F-9
<PAGE> 39
NetMed, Inc.
Notes to Consolidated Financial Statements
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
NET LOSS PER SHARE
The following table sets forth the computation of basic and diluted earnings
per share:
<TABLE>
<CAPTION>
1998 1997 1996
------------ ------------ ------------
<S> <C> <C> <C>
Net loss $(2,638,806) $(3,284,276) $ (592,822)
=========== =========== ===========
Weighted average shares 11,477,392 10,963,978 6,263,924
Effect of dilutive stock options
and warrants N/A N/A N/A
----------- ----------- -----------
11,477,392 10,963,978 6,263,924
=========== =========== ===========
Basic earnings per share $ (.23) $ (.30) $ (.09)
=========== =========== ===========
Diluted earnings per share $ (.23) $ (.30) $ (.09)
=========== =========== ===========
</TABLE>
The outstanding convertible debentures (see Note 4) were not included in the
diluted earnings per share calculation for 1998 or 1997 because the effect
would be antidilutive.
COMPREHENSIVE INCOME
As of January 1, 1998, the Company adopted Statement of Financial Accounting
Standards No. 130, Reporting Comprehensive Income. Statement 130 establishes
new rules for the reporting and display of comprehensive income and its
components; however, the adoption of this Statement had no impact on the
Company's net loss or shareholders' equity. Statement 130 requires unrealized
gains or losses on the Company's available-for-sale securities, which prior to
adoption were reported separately in shareholders' equity, to be included in
other comprehensive loss.
F-10
<PAGE> 40
NetMed, Inc.
Notes to Consolidated Financial Statements
3. INVESTMENT IN NSI
The Company owns stock in NSI as a result of the exercise of warrants and
settlement of certain claims with NSI. The investment is classified as
available-for-sale and is carried at fair value, with the unrealized gains and
losses, net of tax, reported as a separate component of stockholders' equity.
NSI trades publicly on the NASDAQ Bulletin Board under the symbol "NSIX." The
Company sold 140,000 and 43,000 shares of NSI stock which resulted in a gain of
$762,829 and $664,057 during 1997 and 1996, respectively, which was reported as
other income. In addition, the Company used 352,000 and 106,635 shares in
exchange for a reduction of $470,000 and $450,000 in 1998 and 1997,
respectively, in the debentures payable more fully described in Note 4. The
exchange resulted is a loss of $894,147 in 1998 and a gain of $31,990 in 1997.
As of December 31, 1998, the Company owned 98,411 shares of NSI stock at a cost
of $385,864 of which 16,165 shares are pledged as additional security for the
debentures payable. The NSI common stock has been recorded in the accompanying
balance sheet based on its $.25 closing price on December 31, 1998.
4. CONVERTIBLE DEBENTURES
In August 1997, the Company issued $3,000,000 of 6% Convertible Debentures (the
"Debentures") resulting in net proceeds to the Company of $2,743,644 and
recorded associated expenses of $1,106,452 in 1997. Those expenses included
$750,000 representing the 1997 portion of the discount, $100,000 for the cost
of warrants issued to placement agents and the purchasers of the Debentures,
$170,000 in placement fees and $87,000 in professional, stock exchange and
registration fees associated with the Debentures and subsequent registration
statement. The Company recorded an additional $100,000 of finance expense in
1998 to reflect the amortization of the remaining discount on the Debentures.
The Company has reserved 1,500,000 shares for the conversion of the Debentures.
The Debentures are convertible into Common Stock at a conversion price equal to
75% of the average closing price of the Common Stock for the three business
days immediately preceding such time as the debentures are converted (80%
before March 31, 1998) and mature August 13, 2000. The Debentures may also be
redeemed for cash at the Company's option. Interest is accrued and at the
option of the Company may be paid in cash or converted to Common Stock at the
same prices as above. As of December 31, 1998, Debentures with a total
principal amount of $730,000 had been converted into 981,822 shares of Common
Stock.
The Debentures were originally secured by 475,000 shares of common stock of
Neuromedical Systems, Inc. owned by the Company (the "NSI Shares"). During
1998 and 1997, the Company exchanged 352,200 and 106,635, respectively, NSI
Shares for a reduction of $470,000 and $450,000 in the Debentures payable.
F-11
<PAGE> 41
NetMed, Inc.
Notes to Consolidated Financial Statements
4. CONVERTIBLE DEBENTURES (CONTINUED)
In connection with this financing, the Company issued warrants to the
purchasers of the Debentures and to placement agents. The warrants are
exercisable at any time prior to August 13, 2000 at exercise prices of $7.79
per share (for up to 150,000 shares) and $9.35 per share (for up to 65,000
shares).
See Footnote 12 for subsequent event regarding exchange of debentures for
convertible preferred stock of the Company.
5. ACQUISITION OF CERAM OXYGEN TECHNOLOGIES, INC.
On April 3, 1998, the Company acquired from Ceram Oxygen Technologies, Inc.
("COTI") (now known as OxyNet, Inc.) 95 common shares, representing 95 percent
of COTI's outstanding common shares immediately following the closing, in
exchange for a cash payment of $50,000 and delivery of a note in the principal
amount of $150,000 (the "Note"). The Note provided for three equal principal
payments of $50,000 on each of June 1, July 1, and August 1, 1998, together
with interest at the rate of 8.5 percent per annum. The remaining 5 percent of
COTI's outstanding common equity is owned by CeramPhysics, Inc. ("Ceram") of
Westerville, Ohio. COTI holds an exclusive worldwide license to Ceram's
patented oxygen generation technology for all applications of the technology
except oxygen sensors and fuel cells. The consideration was applied by COTI to
payment of a $200,000 license fee owed to Ceram, with $50,000 being paid in
cash, and the balance by assignment of the Note. The acquisition has been
accounted for using the purchase method of accounting with the results of COTI
being consolidated with those of NetMed on a prospective basis beginning April
3, 1998. Unaudited proforma results of operations, assuming the acquisition
had occurred at the beginning of 1997, are presented below.
The pro forma amounts include adjustments that the Company believes are
reasonable.
<TABLE>
<CAPTION>
Twelve Months Ended
December 31
1998 1997
---- ----
<S> <C> <C>
Revenue $399,848 $893,608
Net loss $(2,723,777) $(3,356,750)
Loss per share-
basic & diluted $(.24) $(.31)
</TABLE>
The acquisition was made pursuant to a February, 1997 agreement among the
Company, COTI and Ceram, whereby the Company agreed to make advances to COTI to
complete the fabrication and testing of a ceramic element incorporating the
licensed technology. Pursuant to the agreement, through April 3, 1998, the
Company had advanced $363,470 to COTI for this purpose which was collateralized
by the patents held by Ceram. The agreement also provided that upon completion
of an acceptance test of the ceramic element satisfactory to the Company, the
Company had the right to acquire 95% of the equity of COTI for $200,000.
F-12
<PAGE> 42
NetMed, Inc.
Notes to Consolidated Financial Statements
5. ACQUISITION OF CERAM OXYGEN TECHNOLOGIES, INC. (CONTINUED)
The total cost of the acquisition of $563,470 was allocated to the acquired
assets of Ceram Oxygen Technologies, Inc. (COTI). As the only asset of COTI
was the acquired technology and the underlying license, the entire acquisition
cost was allocated to this asset. The license will be amortized over the
remaining twelve-year life of the patent which underlies the license agreement
with CeramPhysics, Inc. The recorded value of the license will be reviewed
quarterly for indications of impairment. If it is determined that the recorded
value is not fully recoverable, a charge will be recorded in the period that
such a determination is made.
6. STOCK OPTIONS AND WARRANTS
The Company's 1995 Stock Option Plan (the "Stock Option Plan") provides for the
granting of options that may either meet the requirements of Section 422
("Incentive Options") of the Internal Revenue Code of 1986, as amended (the
"Code") or not meet such requirements ("Nonqualified Options"). Key employees,
officers, and directors of, and consultants and advisors who render services to
the Company are eligible to receive options under the Stock Option Plan.
The following represents the activity for the Stock Option Plan for the years
ended December 31, 1998, 1997 and 1996:
<TABLE>
<CAPTION>
1998 1997 1996
Weighted Weighted Weighted
Average Average Average
Number Exercise Number Exercise Number Exercise
Of Options Price Of Options Price Of Options Price
---------- -------- ---------- -------- ---------- --------
<S> <C> <C> <C> <C> <C> <C>
Options outstanding, beginning of year 538,667 $7.92 -- -- N/A
Options granted 574,259 $ .83 538,667 $7.92 -- N/A
Options exercised -- -- -- N/A
Options cancelled (528,000) $7.92 -- -- N/A
Options outstanding, end of year 584,296 $ .96 538,667 $7.92 -- N/A
Options exercisable at year end 414,126 $1.15 55,750 $7.09 -- N/A
</TABLE>
The number and weighted-average fair value of options granted during 1998, 1997
and 1996 is as follows:
<TABLE>
<CAPTION>
1998 1997 1996
Weighted Weighted Weighted
Average Average Average
Fair Fair Fair
Value of Value of Value of
Number Options Number Options Number Options
Of Options Granted Of Options Granted Of Options Granted
---------- -------- ---------- -------- ---------- --------
<S> <C> <C> <C> <C> <C> <C>
Stock price equal to exercise price 574,259 $.28 -- N/A -- N/A
Stock price greater than exercise price -- N/A 225,000 $2.08 -- N/A
Stock price less than exercise price -- N/A 313,667 $5.25 -- N/A
</TABLE>
For the year ended December 31, 1997, the Company recorded compensation expense
of $431,593 for the 313,667 stock options issued at less than market value.
The number of shares available for grants under the Stock Option Plan was
165,074, 211,333 and 300,000 at December 31, 1998, 1997 and 1996, respectively.
F-13
<PAGE> 43
NetMed, Inc.
Notes to Consolidated Financial Statements
6. STOCK OPTIONS AND WARRANTS (CONTINUED)
Pro forma information regarding net income and earnings per share is required
by SFAS No. 123, which also requires that the information be determined as if
the Company has accounted for its employee stock options granted subsequent to
December 31, 1994 under the fair value method of that Statement. The fair
value for these options was estimated at the date of grant using a
Black-Scholes option pricing model with the following weighted-average
assumptions for 1996, 1997 and 1998: risk-free interest rate of 6% for 1996 and
5.75% for 1997 and 1998; no dividend yield; volatility factor of the expected
market price of the Company's common stock of $.62 for 1996 and $.44 for 1998
and 1997 and expected lives ranging from 2 to 5 years.
If the Company had elected to recognize compensation cost based on the fair
value of options at the grant date as prescribed by SFAS No. 123, the following
displays what reported net income (loss) and per share amounts would have been:
PRO FORMA YEARS ENDED DECEMBER 31,
<TABLE>
<CAPTION>
1998 1997 1996
----------- ----------- ---------
<S> <C> <C> <C>
Net (loss) income $(2,956,558) $(3,776,177) $(873,866)
Diluted (loss) income
per share $ (.26) $ (.34) $ (.14)
</TABLE>
The pro forma financial effects of applying SFAS No. 123 are not likely to be
representative of the pro forma effects on reported results of operations for
future years.
During the second quarter of 1998, officers of the Company agreed to reduce
their cash compensation received in exchange for receiving stock options of the
Company. The officers received 3.125 options for each dollar of compensation
reduced. The value of the options was determined using the Black-Scholes
option pricing model. The Company recorded compensation expense of $61,664 in
1998 as a result of this transaction.
During the third quarter of 1998, the Company entered into Replacement Option
Agreements, each dated as of July 21, 1998, with certain Company employees
participating in the Stock Option Plan (each such agreement, a "Replacement
Option Agreement"). Pursuant to the terms of the Replacement Option Agreements,
the Company canceled 321,000 employee stock options at exercise prices ranging
from $4.95 to $12.00 per share and issued 230,140 replacement options, each at
an exercise price of $.50 per share representing the fair market value of the
common stock on the grant date (collectively, the "Replacement Options").
Senior management received Replacement Options covering shares equal only to
66% of their respective original option grant amounts.
F-14
<PAGE> 44
NetMed, Inc.
Notes to Consolidated Financial Statements
6. STOCK OPTIONS AND WARRANTS (CONTINUED)
The following is a summary of the stock option activity for a prior
non-qualified plan (no additional options may be granted under this plan) for
the three years ended December 31, 1998:
<TABLE>
<CAPTION>
NUMBER OF WEIGHTED AVERAGE
SHARES EXERCISE PRICE
--------- -----------------
<S> <C> <C>
NON-QUALIFIED PLAN
Outstanding at January 1, 1996 365,600 $1.74
Issued 56,000 $1.55
Exercised (21,200) $1.53
Expired (64,000) $1.53
-------
Outstanding and exercisable
at December 31, 1996 336,400 $1.76
Issued 16,000 $3.25
Exercised (8,400) $1.83
Expired (16,000) $3.25
-------
Outstanding and exercisable
at December 31, 1997 328,000 $1.76
Expired (32,000) $7.13
-------
Outstanding and exercisable
at December 31, 1998 296,000 $1.18
-------
</TABLE>
The exercisable options for the non-qualified plan had a remaining
weighted-average contract life of 5 years.
F-15
<PAGE> 45
NetMed, Inc.
Notes to Consolidated Financial Statements
6. STOCK OPTIONS AND WARRANTS (CONTINUED)
During 1997 and 1996, the Company extended the expiration date of 16,000 and
56,000 options, respectively, due to expire near the end of the year.
Accounting Principles Board Opinion No. 25 requires that extended options be
treated as if they were a new grant. The exercise price set for these options
was below the market price at the date of grant and resulted in $24,000 in 1997
and $410,000 in 1996 in compensation expense. These options had a
weighted-average fair value and a weighted-average exercise price of $2.11 and
$3.25 for the 1997 extension and $7.60 and $1.55 for the 1996 extension,
respectively.
During 1998, the Company issued a total of 350,000 warrants at exercise prices
ranging from $.75 to $2.50 per share to consultants performing investor
relations activities. The Company recorded consulting expense of $11,000 in
conjunction with the issuance of the warrants. As of December 31, 1998, there
were outstanding warrants to purchase common stock at exercise prices from
$.875 per share to $9.35 per share. The following is a summary of warrant
activity for the three years ended December 31, 1998:
<TABLE>
<CAPTION>
NUMBER OF WEIGHTED AVERAGE
SHARES EXERCISE PRICE
--------- ----------------
<S> <C> <C>
Outstanding at January 1, 1996 and
December 31, 1996 71,020 $1.25
Issued during 1997 215,000 $8.26
=======
Outstanding and exercisable at
December 31, 1997 286,020 $6.46
Issued during 1998 350,000 $1.39
-------
Outstanding at December 31, 1998 636,020 $3.67
=======
</TABLE>
F-16
<PAGE> 46
NetMed, Inc.
Notes to Consolidated Financial Statements
7. INCOME TAXES
Significant components of deferred tax assets and liabilities are as follows:
<TABLE>
<CAPTION>
1998 1997
----------- -----------
<S> <C> <C>
Loss carryforwards $ 2,007,167 $ 1,132,251
Gain on NSI warrants (260,100) (260,100)
Stock options issued 430,328 346,237
Valuation allowance provided (2,177,395) (1,218,388)
----------- -----------
Net deferred tax liability $ -- $ --
=========== ===========
</TABLE>
At December 31, 1998, the Company had unused NOL carryforwards for tax purposes
of approximately $329,000, $320,000, $211,000, $711,000 $1,151,000 and
2,187,000 which expire in 2007, 2008, 2009, 2010, 2011 and 2012 respectively.
At December 31, 1998, a full valuation allowance was recorded due to the lack
of deferred tax liabilities, historical income and tax planning strategies.
The reconciliation of income tax computed at the statutory rate to the recorded
tax provision (benefit) is:
<TABLE>
<CAPTION>
1998 1997 1996
--------- ---------- ---------
<S> <C> <C> <C>
Tax provision (benefit) at statutory rate $(899,185) $ (951,406) $(344,704)
Benefit of state loss carryforward (158,680) (108,189) (76,309)
Permanent differences:
Convertible discount and interest 73,525 313,670 --
Other permanent 4,071 13,559
Valuation allowance provided 980,269 1,218,388 --
--------- ---------- ---------
Total tax provision (benefit) $ -- $ 486,022 $(421,013)
========= ========== =========
</TABLE>
F-17
<PAGE> 47
NetMed, Inc.
Notes to Consolidated Financial Statements
8. NOTE RECEIVABLE FROM STOCKHOLDER
On October 14, 1994, the Company loaned one of its officers and stockholders
$50,000, at prime plus 1/2% interest. Under the loan agreement, effective with
the Merger described in Note 1, the loan was deemed a bonus and converted into
compensation during the year ended December 31, 1996.
9. LEASES
The Company leases facilities and equipment under operating leases.
Commitments for these leases approximate $72,000, $59,000, $59,000 and $43,000
for the years ending December 31, 1999, 2000, 2001 and 2002, respectively.
Rent expense for the years ended December 31, 1998, 1997 and 1996 was $48,000,
$68,798 and $41,677 respectively.
In September 1997, the Company entered into a net lease with Muirfield Square,
Ltd. for 4,900 square feet of office space in which the Company's principal
offices are located. The lease term is for five years at an annual rent of
$53,900 for the first year, escalating annually at the rate of 3% over the
term, and renewable for an additional 5 year term at an annual rental of
$60,660. Certain officers and directors own a majority of the membership
interests in Muirfield Square, Ltd. The Company believes that the lease is on
terms at least as favorable to the Company as office space of a similar size
and quality in the locality.
10. NOTE RECEIVABLE
In April 1997, the Company completed a transaction to accept 16,331 shares of
Company stock for payment of a note receivable valued at $130,143. The number
of shares received in the exchange was based on the market value of the shares
in November 1996 when the method of settling the note was negotiated. The note
was charged to common stock on the accompanying balance sheet as the shares
were retired.
11. PREFERRED STOCK ISSUANCE
In August 1998, OxyNet completed the sale of 500 8% Cumulative Convertible
Preferred Shares (the "Shares") in a private offering, with net proceeds to
OxyNet of $491,000. The net proceeds of $491,000 has been recorded as a
minority interest in the accompanying financial statements. The Shares are
entitled to cumulative dividends at the rate of 8% per annum payable in
additional shares, and are convertible into common shares of OxyNet, Inc. on a
one share for one share basis (subject to adjustments for dilution in certain
events). The Shares were sold with a one time right to exchange them at their
original stated value, plus accrued dividends, for common shares of NetMed, for
a period of 30 days following a date which is 18 months from the date of
issuance, at the then-prevailing market price of NetMed common shares (not to
exceed $3.00 per share), if there has been no initial public offering for common
shares of OxyNet. NetMed is the parent of OxyNet. NetMed would own
approximately 89.1% of OxyNet's
F-18
<PAGE> 48
NetMed, Inc.
Notes to Consolidated Financial Statements
outstanding common shares on a fully converted basis if the preferred shares
are exchanged for OxyNet common stock.
12. SUBSEQUENT EVENT
On January 22, 1999, pursuant to an exchange agreement between NetMed and the
owners of the 6% Convertible Debentures (see Footnote 4), 97,662 Series A, 6%
Convertible Preferred Shares were issued in exchange for the remaining
outstanding principle balance of the Convertible Debentures of $1,350,000 plus
accrued interest of $117,619.
The Preferred Stock is convertible into Common Stock at a conversion price
equal to 75% of the average closing price of the Common Stock for the three
business days immediately preceding such time as the Preferred Stock is
converted. The Preferred Stock may also be redeemed for cash at the Company's
option. Dividends are accrued and at the option of the Company may be paid in
cash or converted to Common Stock at the same prices as above. The Company
will record a preferred dividend financing charge to retained earnings in the
amount of $450,000 to reflect the value of the discount as of the closing date.
13. SEGMENT REPORTING
The Company has adopted FASB Statement No. 131, "Disclosures about Segments of
an Enterprise and Related Information." The Company has determined that it
currently has two reportable segments - the marketing of the PAPNET Testing
System and the pursuit and development of other medical related technologies.
All of the Company's business activities are conducted in the United States,
and there is no reliance on foreign customers or suppliers.
The following table presents information about reported segment profit and loss
and segment assets for the year ended December 31, 1998. Prior to 1998, the
Company had only one reportable segment - the marketing of the PAPNET Testing
System.
<TABLE>
<CAPTION>
DEVELOPMENT OF
MEDICAL
PAPNET TECHNOLOGIES CORPORATE TOTAL
------------ --------------- --------- -----------
<S> <C> <C> <C> <C>
Revenue from external customers $ 399,848 $ 0 $ 0 $ 399,848
Intersegment revenues 0 0 0 0
Interest expense 100,702 3,069 0 103,771
Depreciation expense 18,980 227 0 19,207
Segment loss (2,229,311) 409,495 0 (2,638,806)
Segment assets 61,630 779,142 631,693 1,472,195
Expenditures for long-lived assets 8,280 13,616 0 21,896
</TABLE>
F-19
<PAGE> 49
NetMed, Inc.
Notes to Consolidated Financial Statements
14. GOING CONCERN
The Company has incurred losses of approximately $6.5 million over the past
three years and has negative net worth at December 31, 1998. The Company has
been able to fund its operating losses to date through the receipt of royalty
payments from NSI under the license agreement, the sale of its common stock of
NSI, the sale of common stock, the sale of preferred stock of the OxyNet
subsidiary, and the sale of convertible debentures. Many of these sources of
funding are no longer available to the Company in amounts adequate to continue
to fund operating losses at historic levels. On March 26, 1999, NSI announced
that it had commenced reorganization proceedings under Chapter 11 of the U.S.
Bankruptcy Code, raising a question as to whether the Company can expect to
continue to earn revenues from the marketing of the PAPNET System under its
license from NSI. The ability of the Company to reduce its operating expenses
to a level that can be financed by existing cash and investments is therefore
critical to the Company's ability to continue operating as a going concern.
In February 1999, the Company consummated the exchange of the outstanding
convertible debentures for convertible preferred stock. This exchange
transaction was significant because it eliminated the rights of the debenture
holders to demand a cash redemption of the debentures in the event of default.
The Company is also engaged in discussions with third parties about possible
joint venture arrangements that have the potential for cash payments to the
Company and funding for the continued development of the Company's oxygen
generation technology.
The Company has the ability to reduce operating expenses significantly. The
Company can also discontinue development efforts on the oxygen generation
device. The Company will institute expense reduction measures as necessary to
ensure the solvency of the Company throughout 1999.
F-20
<PAGE> 50
NETMED, INC.
FORM 10-K FOR THE YEAR ENDED
DECEMBER 31, 1998
EXHIBIT INDEX
F-21
<PAGE> 51
EXHIBIT INDEX
EXHIBIT
NUMBER DESCRIPTION
------- -----------
3.1 Amended and Restated Articles of Incorporation of the
Registrant. (Previously filed as Appendix A to the Registration
Statement on Form S-4, Registration No. 333-8199, and incorporated
herein by reference.)
3.2 Amended and Restated Regulations of the Registrant. (Previously
filed as Appendix A to the Registration Statement on Form S-4,
Registration No. 333-8199, and incorporated herein by reference.)
3.3 Form of Specimen Stock Certificate. (Previously filed as
Exhibit 3(e) to the Registration Statement on Form S-4, Registration
No. 333-8199, and incorporated herein by reference.)
4.1 Articles FOURTH, SIXTH, SEVENTH, EIGHTH, TENTH, and ELEVENTH,
of the Registrant's Amended and Restated Articles of Incorporation
and Articles I, V and VII of the Registrant's Amended and Restated
Regulations. (Previously filed as Exhibit 4(b) to the Registration
Statement on Form S-4, Registration No. 333-8199, and incorporated
herein by reference.)
10.1 Amended and Restated 1995 Stock Option Plan of the Registrant.
(Previously filed as Exhibit 10(i) to the Registration Statement on
Form S-4, Registration No. 333-8199, and incorporated herein by
reference.)
10.2 Net Lease between Muirfield Square, Ltd. as Lessor and Registrant
as Lessee, dated September 15, 1997. (Previously filed as Exhibit 10.9
to the Registration Statement on Form S-1, Registration No. 333-35663,
and incorporated herein by reference.)
10.3 Investment Agreement among the Registrant, CeramPhysics, Inc. and
Ceram Oxygen Technologies, Inc., dated February 28, 1997. (Previously
filed as Exhibit 10(j) to Registrant's 1996 Annual Report on Form
10-K, Commission file no. 1-12529, and incorporated herein by
reference.)
10.4 Revolving Loan-Grid Note, between the Registrant as the lender
and Ceram Oxygen Technologies, Inc. as maker, dated February 28, 1997,
as amended December 16, 1997. (Previously filed as Exhibit 10.7 to
Registrant's 1997 Annual Report on Form 10-K, Commission file no.
1-12529, and incorporated herein by reference.)
10.5 Employment Agreement between the Registrant and David J. Richards,
dated as of April 1, 1997. (Previously filed as Exhibit 10(a) to
Registrant's Quarterly Report on Form 10-Q for the quarter ending June
30, 1997, and incorporated herein by reference.)
21 * Subsidiaries of the Registrant
23 * Consent of Ermst & Young, LLP.
24 * Powers of Attorney.
27 * Financial Data Schedule.
99.1 Convertible Debenture Exchange Agreement, dated October 27, 1998,
among the Registrant, CPR (USA) Inc., LibertyView Fund, LLC, and
LibertyView Plus Fund. (Previously filed as Exhibit 99.1 to
Post-Effective Amendment No. 2 to Form S-1 on Form S-3, Registration
No. 333-35663, and incorporated herein by reference.)
F-22
<PAGE> 52
99.2 Registration Rights Agreement, dated October 27, 1998, among the
Registrant, CPR (USA) Inc., LibertyView Fund, LLC, and LibertyView
Plus Fund. (Previously filed as Exhibit 99.2 to Post-Effective
Amendment No. 2 to Form S-1 on Form S-3, Registration No. 333-35663,
and incorporated herein by reference.)
99.3 Amended and Restated Agreement, dated November 23, 1998, between
Neuromedical Systems, Inc. and the Registrant. (Previously filed as
Exhibit 99.3 to Post-Effective Amendment No. 2 to Form S-1 on Form
S-3, Registration No. 333-35663, and incorporated herein by
reference.)
99.4 Registration Rights Agreement, dated August 12, 1997, between the
Registrant and CPR (USA), Inc. (Previously filed as Exhibit 99.4 to
the Registration Statement on Form S-1, Registration No. 333-35663,
and incorporated herein by reference.)
* Filed with this Report.
<PAGE> 1
EXHIBIT 21
Subsidiaries of NetMed, Inc.:
NetMed, Inc. owns 95% of the issued and outstanding stock of OxyNet, Inc.
<PAGE> 1
CONSENT OF INDEPENDENT AUDITORS
We consent to the incorporation by reference in the Registration Statement
(Post-Effective Amendment No. 3 to Form S-1 on Form S-3 No. 333-35663) for the
registration of 1,500,000 shares of common stock of NetMed, Inc. and in the
related Prospectus of our report dated January 29, 1999, except as to Note 14 as
to which the date is March 26, 1999, with respect to the consolidated financial
statements of NetMed, Inc. included in this Annual Report (Form 10-K) for the
year ended December 31, 1998.
Ernst & Young LLP
Columbus, Ohio
March 30, 1999
<PAGE> 1
POWER OF ATTORNEY
-----------------
Each director and/or officer of NetMed, Inc. (the "Corporation") whose
signature appears below hereby appoints David J. Richards, Kenneth B. Leachman,
and William J. Kelly, Jr. as the undersigned's attorneys or any of them
individually as the undersigned's attorney, to sign, in the undersigned's name
and behalf and in any and all capacities stated below, and to cause to be filed
with the Securities and Exchange Commission (the "Commission"), the
Corporation's Annual Report on Form 10-K (the "Form 10-K") for the fiscal year
ended December 31, 1998, and likewise to sign and file with the Commission any
and all amendments to the Form 10-K, and the Corporation hereby also appoints
such persons as its attorneys-in-fact and each of them as its attorney-in-fact
with like authority to sign and file the Form 10-K and any amendments thereto
granting to each such attorney-in-fact full power of substitution and
revocation, and hereby ratifying all that any such attorney-in-fact or the
undersigned's substitute may do by virtue hereof.
IN WITNESS WHEREOF, the undersigned have executed this Power of
Attorney in counterparts if necessary, effective as of March 23, 1999.
SIGNATURE TITLE
/s/David J. Richards President, Director
- ------------------------- (Principal Executive Officer)
David J. Richards
/s/Kenneth B. Leachman Executive Vice President-Finance,
- ------------------------- Treasurer (Principal Financial and
Kenneth B. Leachman Accounting Officer)
/s/Treavor Ferger
- -------------------------
Trevor Ferger Director
/s/Cecil J. Petitti
- -------------------------
Cecil J. Petitti Director
/s/Michael S. Blue
- -------------------------
Michael S. Blue Director
/s/Robert J. Massey
- -------------------------
Robert J. Massey Director
/s/James F. Zid
- -------------------------
James F. Zid Director
/s/Susan M. O'Toole
- -------------------------
Susan M. O'Toole Director
<TABLE> <S> <C>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> YEAR
<FISCAL-YEAR-END> DEC-31-1998
<PERIOD-START> JAN-01-1998
<PERIOD-END> DEC-31-1998
<CASH> 513,712
<SECURITIES> 24,603
<RECEIVABLES> 30,000
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 568,921
<PP&E> 110,254
<DEPRECIATION> 65,302
<TOTAL-ASSETS> 1,472,195
<CURRENT-LIABILITIES> 261,041
<BONDS> 1,350,000
<COMMON> 6,184,968
0
491,000
<OTHER-SE> (7,085,645)
<TOTAL-LIABILITY-AND-EQUITY> 1,472,195
<SALES> 399,848
<TOTAL-REVENUES> 399,848
<CGS> 0
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 1,968,746
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 103,771
<INCOME-PRETAX> (2,644,663)
<INCOME-TAX> 0
<INCOME-CONTINUING> (2,638,806)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (2,638,806)
<EPS-PRIMARY> (.23)
<EPS-DILUTED> (.23)
</TABLE>
